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ABSTRACT
Over 500,000 bone graft procedures are performed each year in the United States.
Bone grafting involves a surgical procedure to replace missing bone. Problems can arise
with donor and defect sites during and after surgery, sometimes resulting in poor clinical
results.

The development and optimization of bone graft substitutes via a tissue

engineering approach could markedly improve bone graft surgical outcome.
Demineralized bone matrix (DBM), a bone graft material, is currently used in a clinical
setting but has variable success rates.
The primary objective of the research presented in this thesis was to assess the
cellular activity of D1 mouse stromal cells seeded on either partially demineralized bone
matrix (PDBM) substrates or completely demineralized bone matrix substrates (CDBM).
Before performing a cell-based experiment involving the varying levels of DBM, a study
was performed to determine the optimal media conditions for osteoblast formation.
Additives β-glycerophosphate and L-ascorbic acid were added to α-MEM media and
cultured with D1 cells on DBM to assess the effects of these additives on the rate of
cellular differentiation.

Significant differences in osteoblast activity were not noted

between the two medium conditions.
The final study evaluated cellular activity at four specific time points over a 36
day period after seeding D1 cells on DBM of varying demineralization levels. Based on
the assays performed at the four time points, it appears that the D1 cells on the PDBM
fragments differentiated toward the osteoblast phenotype and the cellular fragments
began to mineralize between 24 and 36 days after initiation of culture, while the cellular
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CDBM showed minimal potential for mineralization over the course of the study.
Additional studies with more frequent time points are necessary to gain a better
understanding of the cellular activity of the D1 cells on the DBM.
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PREFACE
Hundreds of thousands of surgeries are performed each year to treat orthopedic
defects in spinal surgeries and in the repair of maxillofacial defects, cranial defects, nonunion fractures, tumor removal sites, and in trauma restoration.

Autografts are the

traditional bone graft but the related surgeries are associated with problems such as donor
site morbidity, pain, and infection. As a result, this research is geared toward designing a
suitable bone graft substitute that eliminates problems associated with autografts but is as
effective as an autograft in inducing bone formation to fill voids in bone tissue.
This thesis provides insight into a tissue engineering approach to developing a
novel scaffold for bone grafting. A specific form of allograft is studied during this
research - demineralized bone matrix (DBM).

Although DBM products are used

clinically, variable success rates have been reported. It is believed that some of this
variability may stem from inconsistent processing factors of the scaffold. The research
presented here focuses on determining a medium cocktail which enhances osteoblast
formation and determining the effects of seeding cells on DBM of varying
demineralization levels.
To meet the objectives of this research, two primary studies were performed. The
first study evaluated the cellular activity of D1 mouse stromal cells seeded on partially
DBM scaffolds over a 24 day time period. The activity of cells cultured in two separate
medium conditions were compared to each other to determine which allowed the
differentiation of the cells towards osteoblasts. The first medium cocktail contained αMEM with two osteogenic supplements, β-glycerophosphate and L-ascorbic acid. The

xii

second medium contained α-MEM but no osteogenic supplements.

Once the most

applicable cocktail was discovered in the first study, the cellular activity of D1 cells
seeded on partially demineralized and completely demineralized bone scaffolds was
observed. The cellular activity of cells was observed over time and histological analyses
provided insight into initial mineralization and mineralization that occurred during the
course of the study. The work presented represents preliminary research toward the
consistent development of demineralized bone matrix as a bone graft substitute for
autografts. The results of this research can be used to design and implement future
studies.
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AN IN VITRO EVALUATION OF DBM AS A TISSUE ENGINEERED
SCAFFOLD

LITERATURE REVIEW
Introduction
Approximately 500,000-605,000 bone graft surgeries are performed each year in
the United States and approximately 1,000,000 are performed worldwide [1-4]. Bone
grafts are used to repair bone defects in orthopedics, dentistry, and neurosurgery. More
specifically, bone grafts are used in spinal surgeries and in the repair of maxillofacial
defects, cranial defects, non-union fractures, tumor removal sites, and in trauma
restoration. In humans, bone is one of the most frequently transplanted tissues [5]. In
2001, the global bone graft market was valued at over one billion dollars and bone graft
product sales neared $15 billion [4].

Normal Bone Physiology
Bone is an important tissue in that it provides protection and structural support to
the body. Bone is also involved in the metabolism of minerals and is the primary site for
the synthesis of blood cells. Bone maintains its shape and strength via a remodeling
process [4]. Normal bone is an organized mineralized structure composed of a matrix
and a mineral phase. Amorphous calcium phosphate is the main component of the
mineral phase [6] while the matrix portion is composed of type I collagen and osteoid [6].
Osteoid is an organic protein substance, largely composed of type I collagen, that when
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deposited is considered to be unmineralized bone matrix [7].

When the osteoid is

converted from the organic phase to the inorganic phase, mineralization is thought to
occur. Mineralization of bone increases the density but not the volume of the bone [8].
The exact mechanism of mineralization is still unclear.
Bone is modeled during the developmental and growth phases of development.
Modeling is achieved by the removal of bone from one site followed by the deposition of
new bone at another site while remodeling occurs when mature bone is replaced with new
bone.

Over a 10 year span, the entire human skeleton is thought to remodel [8].

Osteoclasts and osteoblasts work together as a unit to remodel bone [8]. Bone is removed
by osteoclasts via acidification and proteolytic digestion during the process of resorption
[8]. Osteoblasts then move into the area where bone was removed and secrete osteoid.
Osteoblasts produce type I collagen as well as many proteins such as osteocalcin,
osteonection, osteopontin, bone sialoprotein, and fibronection [8]. Osteoblasts regulate
calcium and phosphate concentrations so that hydroxyapatite is formed. The process of
mineralization of bone is thought to occur once hydroxyapatite is deposited. Osteoblasts
also produce large amounts of alkaline phosphatase (ALP), which appears to also play a
large role in bone mineralization [8, 9].

Current Bone Grafts
Autologous bone grafts constitute tissue that is removed from the patient and then
implanted back into the same patient.

Autografts are considered the current gold

standard, because the tissue is a perfect match to the patient, there is minimal chance for
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an immunogenic reaction [10], and they have the highest success rate of clinically
available bone grafts [11]. Autografts contain three essential bone properties that support
and induce bone formation: osteoconductivity, osteoinductivity, and osteogenecity [2,
12]. The osteoconductive property of a bone graft refers to the graft’s ability to provide
structural support and allow the in-growth of blood vessels and bone cells [13]. The
ability of a bone graft to induce bone formation via recruitment of precursor osteoblastic
cells is termed osteoinduction. When bone grafts are osteoinductive, it is thought that
mesenchymal cells are recruited to the scaffold.

After reaching the scaffold, the

mesenchymal cells have the ability to differentiate into osteoblasts [13]. Osteogenecity is
the ability of the bone graft to induce bone formation, due to the presence of precursor
stem cells that can differentiate and produce bone directly [14, 15].
Although autologous grafts are the gold standard in bone grafting, there are many
drawbacks to this type of graft and affiliated procedure. A limited amount of harvestable
bone is available for autograft procedures; the primary donor site is the iliac crest with
less frequently tapped donor sites being the distal femur or the proximal tibia [1, 16].
Although the iliac crest is usually a good source of quality cancellous bone, the harvested
bone can be difficult to shape since the retrieved bone has variable shape and thickness
[2, 17]. Patients who have already had a bone graft surgery may not be good candidates
for future autograft procedures. Two surgery sites are required when an autologous bone
graft is used, one at the donor site and one at the implantation site. The donor site can be
painful, undergo morbidity, as well as become infected, suffer from increased blood loss,
have a slow return to normal function [4, 15, 18, 19], and have increased susceptibility to
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infection. These disadvantages can lead to higher healthcare costs and longer recovery
times for patients [12].
When an alternative to autografts is warranted, allografts can be used instead.
Allografts involve the transplantation of tissue from one member of a species to another
member of the same species.

Currently, cadaver allografts are the most common

alternatives used in place of autografts [19]. Unlike the autograft, there is an abundant
supply of bone that can be harvested for an allograft procedure [20]. Allografts allow the
patient to undergo only one surgery site which can lower the costs involved in the
procedure, shorten the hospital stay, and eliminate the problems associated with a second
surgical site that evolve from the retrieval of bone for an autograft.
Allografts also have limitations; they are osteoconductive, but not osteoinductive
[21, 22]. Allograft bone cannot always initiate osteogenesis; therefore, autograft tissue
may be used in conjunction with the allograft tissue [20]. This method re-introduces the
problem of a second surgery site that clinicians try to avoid by using allografts instead of
autografts. Since the donor bone is explanted from a cadaver, there is a chance of disease
transmission from the donor to the patient [19, 23]. Immunological reactions can cause
decreased bone formation and can result in immunorejection of the graft [24].

An

allograft can also be hard to shape to conform to a bone defect [23]. Each bone graft site
is different, therefore is it necessary that a bone graft product be able to readily conform
to the damaged area.
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Tissue Engineering
Tissue engineering was defined by Langer and Vacanti as an “interdisciplinary
field that applies the principles of engineering and life sciences toward the development
of biological substitutes that restore, maintain, or improve tissue function or a whole
organ” [25]. There are three general strategies for designing tissue engineered devices
[25].

The first strategy involves isolating cells from the patient or designing and

constructing cell substitutes and then manipulating them to perform a specific function
before being placed back into the patient [25]. An advantage to this type of procedure is
that surgical procedures are eliminated and that only cells that supply a specific function
are replaced. One drawback to cell isolation is immunological rejection and failure of the
cells to perform their specific function once placed into a patient [25]. The final two
strategies for tissue engineering, as described by Langer (1993), are the utilization of
tissue-inducing substances and the placement of cells on or in matrices.
matrices include natural materials and synthetic polymers.

Common

The success of tissue

engineering necessitates understanding tissue behaviors such as function and
regeneration.
The aim of bone tissue engineering is to design and produce a bone substitute that
is comparable or superior to an autograft. As the number of bone graft procedures
increase, approximately 7-10% each year since 2001, the bone graft market expands as
does the need for alternative products that do not have the drawbacks associated with
traditional autografts and allografts [16]. The goal of using bone grafts is to allow a bony
defect to be filled with bone similar to that of natural tissue by promoting bone formation.
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Patient

Implant scaffold
using a noninvasive surgical
method
Biopsy/cell
source

Culture
Scaffold

Isolate and
expand cells

“””””””]=[

Scaffold + cells
+ growth factors

Construct 3-D
matrix

Figure 1 An example of tissue engineered bone generation.
A biopsy is removed bone from the patient (or donor in case of an allograft). Cells are
isolated from the harvested tissue and constructed into a 3-D matrix. Growth factors and
the isolated cells are added to the 3-D matrix and cultured to form a suitable implant.
The scaffold is then placed into the patient [13, 26].
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Several criteria have been defined by researchers and clinicians as ideal properties
of tissue engineered bone grafts.

Tissue engineered bone grafts should be free of

problems that are associated with autografts and they should shorten recovery times for
the patient [16]. Bone grafts should be osteoinductive, osteoconductive, and osteogenic
[27]. The scaffold (used interchangeably with matrix in this thesis), should be easily
sterilized without the reduction of mechanical or physical characteristics [28]. Ideally,
bone graft scaffolds should be biocompatible, absorbable or degradable, highly porous,
similar in structure to natural bone, cost-effective, easily manufactured as a commercial
product, and easy to handle [2, 16, 28-30]. It is not clear whether or not the scaffold need
have mechanical properties similar to natural tissue. Some researchers postulate that this
point is not necessary because the primary function of the scaffold is to support bone ingrowth, while others believe it is to provide a mechanically stable environment [28].

Demineralized Bone Matrix
Allograft demineralized bone matrix (DBM) may be harvested from a cadaver
and, after processing, transplanted into another patient. DBM is prepared by decalcifying
bone particles to produce an organic matrix which contains collagen and proteins [15,
19].

The mineral phase is removed by chemicals that chelate or solubilize the

mineralized phase [31]. Ethylenediaminetetraacetic acid (EDTA) is an example of a
chelating agent that researchers use for demineralization. The drawback to the use of
EDTA is that it leaves the matrix devoid of osteoinductive factors [31]. In general, it is
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thought that acid solubilization may weaken the overall matrix [31].

HCl, another

demineralization agent used by researchers, leaves an osteoinductive matrix [31].
Once implanted into a bony defect in a living body, a successful DBM graft will
stimulate bone formation, likely because the organic matrix is preserved during
demineralization and the low molecular weight proteins remain in the matrix [19, 32].
These proteins become more accessible as the mineral phase is removed from the bone
[2].

Bone morphogenetic proteins (BMPs) and other noncollagenous proteins are

believed to recruit and stimulate mesenchymal cell progenitors to differentiae into
osteoblasts [32, 33]. It is believed also that DBM contains transforming growth factorbeta, osteogenin, insulin-like growth factor, and fibroblast growth factor; all of which are
thought to be involved, either directly or indirectly, in the bone healing cascade [34].
Demineralized bone matrix was reportedly first used in 1889 when Nicholas Senn
reconstructed bony defects with decalcified oxen tibia [14, 35]. Following this initial
discovery, DBM did not gain the interest of many researchers and clinicians [14, 19, 35]
until Urist implanted acid demineralized bone into extraskeletal sites, resulting in the
development of bone ossicles (1965). Two years later, Dubuc and Urist showed that even
when bone fragments are surface decalcified, bone induction occurs [36]. The bone
induction principle is the manner by which new bone is formed by the attraction of
mesenchymal stem cells (MSCs) but not by recalcification of the implanted bone graft.
In the same in vivo study, it was demonstrated that prolonged exposure of bone fragments
to HCl, saline and 70% ethanol causes the bone induction principle to be void. It was
also seen that the surfaced demineralized bone fragments, which were demineralized in
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0.5 N HCl for 1-2 hours, had a larger amount of new bone formation than the completely
demineralized bone fragments which were in 0.5 N HCl for 1 week [37]. It has been
suggested that this outcome might be caused by a high number of macrophages and giant
cells destroying the completely demineralized bone graft. Dubuc and Urist also suggest
that completely demineralized bone fragments might allow bone formation via the bone
induction principle more rapidly than what is desired [37]. The theory proposed by
Duboc and Urist about completely demineralized bone fragments was later corroborated
by Shih in 2005 when he suggested that the mineral in partially demineralized bone may
dissolve slowly, allowing a slow and steady release of BMP’s, while CDBM released the
BMPs at a faster rate [38]. It was noted in the 1960’s that when demineralization factors
such as the exposure time, the ambient temperature, and the concentration of HCl were
controlled there was consistent osteoinduction by the decalcified bone [39]. In 1970,
Urist and Strates reported, in a study involving implantation of DBM in rabbits, that the
amount of demineralization was directly proportional to the amount of bone formation.
In separate studies in the 1960’s and 1970’s, it was demonstrated that diaphyseal bone
from the humerus, femur, tibia, and the fibula showed high levels of osteoinduction while
other soft tissues such as the pelvis, scapula, and all cartilage (except costal rabbit
cartilage) showed little to no osteoinductive properties [39]. In 1979, Urist discovered
BMPs, which are considered the DBM’s main bone induction agent [39]. Zhang reported
in 1997 that bone decalcified to a 2% residual calcium level had a higher amount of
osteoinductivity than fragments with either higher or lower amounts of residual calcium.
Bone fragments were demineralized in 0.5 N HCl for 180 minutes to reach this level (2%)
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of residual calcium. It was also noted that as the residual calcium level decreased from
32.7% to 2%, the osteoinductivity increased in the in vivo model studied. As the residual
calcium level decreased below 2%, the level of osteoinductivity was lower than that
observed of the DBM fragments with 2% residual calcium.
promising results clinically.

DBM has also shown

In 1999, Russell and Block evaluated results from 21

clinical cases in which DBM was used as a bone graft and reported that 80% of these
cases had successful outcomes [21].
DBM can be loaded with other products in order to maximize bone formation. In
2001, Gitelis and coworkers showed that 42 out of 44 bone repair patients had greater
than 80% bone repair when a graft composed of DBM and calcium sulfate was used [14].
Four years later, Mauney seeded bone marrow stromal cells (BMCs) on DBM of various
demineralization levels. The results showed that fragments with partially demineralized
bone (PDBM) had the highest frequency of bone formation when implanted into athymic
female mice, while fully demineralized and fully mineralized bone fragments showed the
same frequency of bone formation, but lower than that of the PDBM [33]. Mauney also
suggested that when bone is over demineralized the osteogenic factors are removed and
the hydroxyapatite nucleation sites, which are essential for new bone formation, may be
depleted [33]. In 2005, Thomas reported that while using an in vitro model comparing
surface demineralized, partially demineralized, and completely demineralized bone
fragments, no difference in the cellular activity between the fragment types was observed,
although osteoblast formation was noted on all substrates [13]. This observation may be
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attributed to the procedures that were followed or because the in vitro study that was used
was not accurate enough to obtain results similar to those received in in vivo studies.
DBM is successful because it contains osteoinductive and osteoconductive
properties. DBM is biocompatible, biodegradable, cost effective, and readily available
[18, 40, 41]. DBM stimulates revascularization quickly, allowing bone formation in a
timely manner [42]. Urist reported that when bone fragments were decalcified in 0.5 N
HCl and implanted into an extraskeletal site, bone formation consistently occurred 25
days after the operation [43]. The demineralization process destroys antigenic substances
that are present in the bone [40, 41]. Pathogens are likely also destroyed during the
processing of the DBM [24]; one manufacturer reported that in 1.5 million procedures
involving one type of DBM, there were not any reported cases of infectious diseases
transmission [42]. A large tissue bank with over 20,000 donors also reported no disease
transmission [42]. These statistics suggest that DBM may provide a superior bone graft
substitute as compared with traditional allografts because DBM is less likely to invoke an
immune response.

Mechanism of Action
It is believed that DBM does not recalcify when implanted into muscle; rather, the
DBM produces new bone via induction [36, 44].

Bone induction leads to the

development of lamellar bone as well as the recruitment of new marrow cells [36]. The
bone induction process that occurs in response to implantation of DBM can be broken
down into four events [39]. Although the exact timing of these events varies between
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studies, the general timing and order of the mechanism is similar. After the inflammatory
phase is initiated on Day 1 following implantation of DBM, MSCs migrate into the
matrix within 2 days of implantation during this initial event. Event 2 occurs between the
2nd and 18th days, when the MSCs differentiate into giant cells and chondrocytes [39, 45].
The third event involves the development of cartilage in poorly vascularized areas
between Days 8 and 20 and the formation of woven bone in vascularized areas of the
matrix between the tenth and twentieth days [39]. Calcification of the cartilage matrix
begins by Day 11 or 12 and is subsequently followed by chondrolysis (dissolution of
cartilage) [45]. The cartilage tissue is eventually replaced by osseous tissue [45]. The
final event includes the production of bone marrow between Days 20 and 30 [39, 46].

Limitations of DBM
It has been reported that clinical results describing DBM application have been
highly variable. One possible reason for failure is that the graft material causes an
inflammatory response which accelerates graft degradation and subsequently leads to
premature degradation and failure of the graft [47]. It is also believed that the nonuniformity in the processing of the DBM by bone banks and commercial suppliers leads
to variable clinical results [2, 12, 46, 48]. DBM is denatured at temperatures above 45°C
so any processing technique which causes an increase in temperature above 45°C can
have detrimental impacts on the overall ability of DBM to induce bone formation [41].
The osteoinductive and osteogenic levels of DBM may be affected by the donor gender,
donor age, medical status of the donor at death, length of time before the bone is
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harvested from the donor, implantation site, size of the bone fragments, geometry of the
bone fragments, amount of demineralization, and the storage conditions [42, 48-51]. It is
also possible that the osteoinductivity levels of DBM vary between species which would
explain why the success levels in humans and animals differ [50].
Sterilization procedures can also affect the osteoinductive properties of DBM.
The most common methods researched include ethylene oxide (EtO), autoclave, and
gamma radiation. EtO can react with water and chloride ions to form a toxic compound,
ethylene chlorohydrin (ECl) [47]. This reaction can occur if the graft material still
contains residual ethylene oxide components after sterilization; however, exposure to
vacuum minimizes this risk [24]. DBM should not be autoclaved before implantation
because the osteoinductive potential will be destroyed [39]. Gamma radiation has shown
that even when it is used to sterilize DBM, the DBM is still viable although some believe
that new bone formation is dependant on the dose of gamma radiation [24, 39]. Ethanol
is a disinfectant, not a sterilant, because it does not kill spores and certain viruses [39].
Therefore, EtO and gamma radiation are considered to be the most effective DBM
sterilants.
The non-uniformity of processing bone grafts, the donor status at the time of
harvest, the size and shape of the bone graft, the amount of demineralization and the
sterilization procedures all have the ability of affecting the clinical outcomes of the bone
graft [22]. Schwartz studied demineralized freeze-dried bone allografts (DFDBA), with
fragment sizes of 200-500 microns, from six bone banks to determine their ability to
induce bone formation [50].

Fragments from select bone banks demonstrated
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osteoinductive properties while DBM from other bone banks did not. Testing of two
different batches from the same bone bank showed high variability, where one set of
DBM showed osteoinductive tendencies while the other did not [50]. This study showed
that the different processing procedures employed by bone banks affects the
osteoinductive properties of DBM, and that DBM from the same bone bank also differs
in its ability to induce bone formation [50]. It has also been suggested that the bone
fragment processing variables produce far greater widespread distribution in the clinical
outcomes of DBM than can be attributed to the bone source [22].
As bone particles undergo demineralization, they lose some of their structural
strength as the mineral phase of the bone is removed [2]. Depending on the form of
DBM used, the DBM can be hard to handle and place into a bone defect site [19]. When
used as a powder, DBM has a tendency to migrate from the graft site due to bleeding
[19]. To minimize these problems, DBM is often supplied as a gel, a putty, flexible
strips, a moldable paste with bone chips, or an injectable bone paste [2].

The

osteoinductive properties of DBM is enhanced in clinical and research settings by
creating a gel from bone chips with the addition of either glycerol, hyaluronic acid, or
poloxamer 407 [19]. Bone marrow cells seeded on DBM appear to accelerate bone
healing in rats.
Current research methods are expensive and use many in vivo studies. Until
recent years, bone tissue engineering has focused on in vivo models and, to a lesser
extent, in vitro models [52]. In vitro models can be used to screen implants before
insertion into an animal and to optimize conditions for bone tissue engineering
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applications [52]. In vitro models are also used to evaluate the effects of various implant
properties, such as scaffold composition and architecture, cell-seeding density, and length
of culture on cell growth and development [52]. In vivo testing explores the overall
biocompatibility of the implant material. There is a need to design and implement in
vitro models for bone tissue engineered implants that accurately resemble the in vivo
environment. Such models would help optimize constructs before testing in animals,
which would reduce the cost and number of animals needed for in vivo studies.
Currently, there is not an accurate in vitro model that can be used in studies involving
DBM to predict in vivo behavior.

Research Aims
Currently, DBM is a solution to problems associated with autografts and
allografts in a clinical setting [24]. DBM has been used successfully in clinical surgeries
such as revision arthroplasty, spinal fusion, non-union fractures, dental augmentation,
craniofacial defects, joint surgery, and as a graft substitute [19, 22]. Although DBM is
used increasingly each year, it is not an optimal autograft bone substitute due to
variability in the clinical success rate of the DBM related procedures.
As the need for alternatives to autografts and allografts continue to increase, the
need to optimize tissue engineered grafts also continues to increase. Since processing
factors contribute highly to the variability in the success rate of demineralized bone
matrix products, it is vital that research is completed to determine the effects these factors
have on the ability of DBM to stimulate bone formation.
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The goal of this research was to perform an in vitro analysis to determine the
effects of cellular activity when cells are seeded on demineralized bone matrices of
varying mineralization levels. A protocol previously used by Thomas [13] was employed
to defat bone fragments in a mixture of chloroform and methanol, demineralize the
fragments in 0.5 N HCl, lyopholize the fragments, and sterilize them in ethylene oxide.
The bone was seeded with cells and the cellular activity was observed. A preliminary
study was completed to determine if additives that were added to the media for in vitro
studies involving DBM, specifically L-ascorbic acid and β-glycerophosphate, improve
the ability of the cells to differentiate towards osteoblasts. This study was completed by
comparing partially demineralized bone seeded with cells with two types of media: media
containing the differentiation additives and media without these additives. The overall
objective of the research was thus to determine the effects of a specific processing factor,
the level of demineralization of the bone fragments. The cellular activity of cells seeded
on partially demineralized bone fragments were compared to the cellular activity of bone
fragments that were completely demineralized. All other processing factors remained the
same during this study.
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MATERIALS AND METHODS
Two studies were performed in order to meet the specified objectives of this
research.

The first study entailed seeding cells onto partially demineralized bone

fragments and studying two medium conditions. A second study was performed to
evaluate the effects of the demineralization level on cellular activity over time, after
development and optimization of the methods for demineralization of the bone fragments
and analysis of the cell culture between the two medium conditions,. In both studies,
microscopic images were captured to assess cellular attachment, real-time quantitative
testing was carried out to gain an overall understanding of the metabolic activity of the
cells in culture, and post-study testing was conducted to monitor differentiation of the
cells and the mineralization of the bone. The expression of osteoblastic genes in the cell
culture was monitored in the final study.

Evaluation of Media Cocktails

The purpose of the first phase of this research was to examine the effects of
osteogenic supplements added to medium to culture cells seeded on DBM. DBM is
synonymous with scaffold for the rest of this publication. Substrate preparation was
modified from a previous protocol [13]. The cell culture was evaluated to determine if
osteogenic supplements affect the activities of cells seeded on DBM.
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Bone Matrix Preparation
A modified version of Urist’s protocol [13] was used to defat and demineralize
bovine bone. Diaphyseal cortical sections of bovine femurs were obtained from two
freshly slaughtered cows from the Clemson University Meat Lab (Clemson, SC). Cow
carcasses were stored at approximately 2.2ºC for 14-21 days before the femurs were
removed. Once the femurs were obtained, tissue was removed from the diaphyseal
section and then frozen at -80ºC. A total of two femurs were obtained from two cows on
separate processing dates. The bone was sectioned with a band saw and cut into pieces
approximately 1 cm x 1 cm x 2 cm (Delta Machinery, Jackson, TN) and then frozen at 80ºC. Sectioned bone from two cows was added to an A 11 basic Analytical mill (IKA®
Works, Wilmington, NC) to grind the bone. Fragments in the range of 0.86 - 1.91 mm
were collected using a Cellector® Tissue Sieve System (PGD Scientifics, Frederick, MD)
with mesh screens of size 20 and 10, respectfully. A total of 26 mL of ground cortical
bone was collected.
Bone fragments were added to a glass bottle containing a defatting solution which
consisted of a 3:1 volume of a chloroform/methanol solution (58.5 mL of chloroform
(Acros, NJ) and 19.5 mL of methanol (Fisher Scientific, Fairlawn, NJ)). The glass bottle
was sealed with a top and the contents were stirred at 4ºC for two hours. The spent liquid
was removed and 58.5 mL fresh defatting solution was added to the glass bottle and the
process was performed a second time. After the second removal of the defatting solution,
the bone fragments were washed in one volume (26 mL) of 100% ethanol for 30 minutes
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at 4ºC; the ethanol was then removed and the fragments were placed in a clean glass
bottle and stored at 4ºC for approximately 11 hours.
The bone fragments were demineralized in ten volumes of 0.5 N HCl (260 mL)
(Fisher Scientific) at room temperature. The solution was stirred continuously at 40
minute intervals.

Stereomicroscopy was performed to determine the level of

demineralization after each 40 minute cycle using an EMZ stereomicroscope (Meiji
Techno, San Jose, California). Digital images of bone fragments were captured using a
SPOT INSIGHT digital color camera and software (Diagnostic Instruments, Sterling
Heights, MI) and analyzed with Image-Pro Plus 4.5 Software (Media Cybernetics,
Bethesda, MD). The remaining fragments were washed with large volumes of distilled
water to neutralize the remaining acid and to remove any mineral residue. Partially
demineralized bone fragments (PDBM) were obtained following two 40 minute acid
cycles.
A negative control (NDBM) was prepared by adding approximately 5.5 mL of
PDBM to 40 mL of guanidine hydrochloride (GnHCl) in 50 mM Tris buffer (pH 7.4)
(both from Sigma, St. Louis, MO) to inactivate the osteoinductive proteins. The solution
was stirred at 4ºC for 16.5 hours and then rinsed in distilled water at room temperature.
The activity of the osteoinductive proteins in the bone fragments was preserved
by lyophilizing the fragments [36, 53] with a BenchTop “K” Series freeze dryer (VirTis,
Cardiner, NY). The bone fragments were sterilized at room temperature in a 12-hour
ethylene oxide (EtO) infiltration cycle in an AN74i sterilization chamber (Andersen
Products, Haw River, NC) followed by two hours of degassing in the same chamber. The
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samples were placed in a dessicator for 57 hours under vacuum (500 mm Hg) until
conditioning.

Cell Seeding
One day prior to cell seeding, the sterilized bone fragments were conditioned in
sterile 50 mL centrifuge tubes to ensure all residual HCl was removed. The fragments
were washed twice in 10 minute intervals in sterile phosphate buffered saline (PBS)
(Sigma). The wash was immediately followed by five 30-minutes rinses and one 12-hour
rinse in Minimum Essential Medium (α-MEM) (Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (FBS) (Mediatech, Herdon, VA) and 1.0% AntibioticAntimycotic (Invitrogen). This supplemented medium will be denoted as α-MEM-C.
The medium contains phenol red which changes color with change in local acidity. The
medium will appear orange to yellow as the pH decreases
While the conditioning process was conducted, twelve tissue culture grade 24well plates (Costar, Corning, NY) were coated with Sigmacote® (Sigma) to form a
hydrophobic surface on the bottom of each well. The plates were left to dry in a sterile
hood for two hours. Days 4, 13, and 24 were selected as time points at which to monitor
changes in cell differentiation. Four 24-well plates were set up per time point; therefore,
a total of 12 plates were used for the media study.
After the conditioning cycle was completed, fresh medium was added to each set
of bone fragments. The tips of glass pipets were modified with a band saw to allow a
wider tip for bone fragment transfer. The modified EtO sterilized pipets were used to
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transfer 0.1 mL aliquots of bone fragments to corresponding wells, as portrayed in Figure
2. One mL of fresh α-MEM-C was then added to each well. The well plates were placed
in a sterile hood overnight.
Osteogenic supplements consisting of 10 mM β-glycerophosphate and 50 µg/mL
ascorbic acid (both from Sigma) were added to α-MEM-C to form α-MEM-M. The spent
media was aspirated from the well plates on the day of cell seeding, and replaced with 1
mL of either α-MEM-C or α-MEM-M, as displayed in Figure 2. Multipotent mouse
marrow stromal cells (D1’s) (#CRL-12424, ATCC, Manassas, VA) were seeded into
each well at a density of 3 x 105 cells/well at passage 33. The negative control group
received bone fragments and medium, but no cells. All well plates were placed in an
incubator under standard conditions of 37ºC and 5% CO2 on an orbital plate (IKA®
Works), shaking at a speed of approximately 50 rpm. The day of cell seeding was
denoted as Day 0 of the study. The media was changed on Days 2, 4, 6, 8, 10, 12, 13, 15,
17, 19, 21, and 23 during the 24-day study.
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D1

acellular

PDBM

α-MEM-M
PDBM

α-MEM-C
NDBM

α-MEM-C

1 plate/time point for gene expression
1 plate/time point use for BCA, ALP, then calcium assays
1 Day 24 plate used for lactic acid/glucose and Alamar Blue™ for all time
points
Total of 6 plates prepared with this layout

D1

acellular

PDBM
α-MEM-M

PDBM
α-MEM-C

NDBM
α-MEM-C

1 plate/time point for cell viability
1 plate/time point for histology
Total of 6 plates prepared with this layout
α-MEM-M and bone fragments
α-MEM-C and bone fragments

Figure 2 Plate and media set-up for the media study
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Qualitative Microscopy
Cell Viability
A LIVE/DEAD® Viability/Cytotoxicity kit (Molecular Probes, Eugene, OR) was
employed according to the manufacturer’s protocol to analyze the cells on the bone
fragments and to determine if the media conditions affected the viability of the cells on
Days 4, 13, and 24. Working solutions were formed by adding 20 µL 2 mM Ethidiumhomodimer-1 (EthD-1) and 5 µL of 4mM calcein AM to 10 mL of sterile PBS in a sterile
15 mL centrifuge tube. All bone fragments specified for this assay were moved to fresh
sterile 24-well plates and then rinsed in sterile PBS to remove any residual medium. The
PBS was aspirated and one mL of the working solution was added to each well. The
plates were incubated for 45 minutes at room temperature in a place void of light.
Images were captured using an Axiovert 135 microscope (Zeiss, Thornwood, NY), a
ProgRes™ C10Plus digital color camera and ProgRes Capture Basic 1.2 software (both
from Jenoptik, Jena, Germany). The images were analyzed with Image-Pro Plus 5.1
Software (Media Cybernetics). The cells were fluorescently labeled using the calcein
AM and ethidium homodimer dyes in the kit and following the manufacturer’s protocol.
Live cells retain a dye that produces bright green fluorescence (excitation and emission of
495 nm and 515 nm, respectively), while dead cells fluoresce a bright red (excitation of
495 nm and emission of 635 nm).
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Histology
Samples from Days 4, 13, and 24 were analyzed using histological techniques. At
each specified time point, the fragments were rinsed twice in sterile PBS (Sigma) and
then fixed overnight in 10% neutral buffered formalin at 4°C. Samples were placed in a
Tissue Tek™ VIP automatic tissue processor (Miles Scientific, Mishawaka, IN) and
processed with a 24-hour dehydration cycle in ethanol, as shown in Table 1. Samples
were infiltrated under vacuum (500 mm Hg) in ascending concentrations of Immuno-Bed
modified glycol methacrylate (I-GMA) (Polysciences, Warrington, PA) as detailed in
Table 2. After two cycles in 100% IGMA, the samples were blotted dry and transferred
to embedding trays. The samples were embedded with fresh IGMA according to the
manufacturer’s protocol and then stored in a dessicator under vacuum (500 mm HG) at
4°C. Samples were placed in a 35°C oven to complete the hardening process and stored
in a dessicator at room temperature until sectioning. Eight micrometer sections were
obtained using a RM2155 rotary microtome (Leica, Bannockburn, IL). Sections were
stained with hemotoxylin and eosin (H&E) and von Kossa to study the cellular
attachment on the bone fragments as well as the mineralization of the bone, respectively.
Protocols can be found in Appendices A and B. Images were captured using an Axiovert
135 microscope (Zeiss), a ProgRes™ C10Plus digital color camera and ProgRes Capture
Basic 1.2 software (both from Jenoptik). The images were analyzed with Image-Pro Plus
5.1 Software (Media Cybernetics).
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Table 1 Ethanol dehydration series for histology samples

Percent
EtOH
70
80
95
95
100
100

Time
(hours)
2
2
3
5
5
7

Table 2 IGMA infiltration series for histology samples

Percent
I-GMA
10
20
30
40
50
60
70
80
90
100
100

Time
(hours)
≥24
≥24
≥24
≥24
≥24
≥24
≥24
≥24
≥24
≥24
≥24
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Real-Time Quantitative Testing

Metabolic Activity
Lactic Acid and Glucose
The lactic acid and glucose levels were analyzed before every medium change
and on the last day of the study, which occurred on Days 2, 4, 6, 8, 10, 12, 13, 15, 17, 19,
21, 23, and 24. Before the medium was aspirated, 200 µL of spent media was removed
from each well and analyzed using a YSI 2700 SELECT™ biochemistry analyzer (YSI,
Yellow Springs, OH). The analyzer determines the glucose and lactic acid concentrations
simultaneously via an immobilized enzyme membrane technology. Specifically, a sipper
withdraws 25 µL of each medium aliquot and deposits it in a chamber where it is stirred
and diluted with buffer. The buffer/aliquot mixture diffuses through a polycarbonate
membrane and contacts a thin layer of an oxidase enzyme (L-lactate oxidase for lactic
acid and glucose oxidase for glucose).

Upon contact, a hydrogen peroxide (H2O2)

product is formed. H2O2 then diffuses toward a platinum anode which causes a current to
be produced at an electrochemical probe. The current value is compared to calibration
values and the concentration of both substrates is given.

Alamar Blue™
The metabolic activity of the cells seeded on the demineralized bone fragments
was assessed on Days 4, 13, and 24 using an Alamar Blue™ dye (BioSource International,
Carmarillo, CA). The spent media was aspirated at these time points, and replaced with
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either fresh α-MEM-C or α-MEM-M after aliquots were removed for lactic acid and
glucose level determination. The well-plates were placed in an incubator at 37°C and 5%
CO2 for four hours. Alamar Blue™ dye was added in 100 µL quantities to each well
before the particular well plate was placed back in the incubator for an additional three
hours to allow uptake of the dye into the metabolically active cells. Medium aliquots
were transferred in triplicate to a black 96-well plate (Corning). The fluorescence values
were read on a SpectraMax® Gemini EM Dual scanning spectrofluorometer (Molecular
Devices, Sunnyvale, CA). The excitation and emission filters were 544 nm and 590 nm,
respectfully. As the nonfluorescent blue dye undergoes reduction in metabolically active
cultures, the dye become pink and fluorescent which allows visual observation of change
in the level of metabolic activity of the cells. This assay is not endpoint assay, therefore
the remaining medium in the 24-well plates was aspirated and replaced with 1 mL of
fresh medium. Results from this assay and the lactic acid and glucose assays were used
to assess cellular metabolic activity.

Post-Study Quantitative Testing
The 24-well plate specified for post-study quantitative testing at each time point
was rinsed twice in sterile PBS (Sigma). Following the rinse, 1 mL of 0.5% Triton-X
(Fisher Scientific) in PBS (Sigma) was immediately dispensed in the plates. The plates
were frozen at -80°C until the plates for all time points were collected. The plates
underwent three freeze/thaw cycles to lyse and release the proteins from the scaffolds in
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preparation for alkaline phosphatase and intracellular protein assays. The remaining cell
lysate and bone fragments were reserved for the extracellular calcium assay.

Intracellular Protein
The intracellular protein content was determined using a BCA Protein Assay
Reagent Kit (Pierce Biotechnology, Rockford, IL) and following the manufacturer’s
protocol. BSA standards were prepared in a 24-well plate using deoionized water as a
dilutant as shown in Table 3. A working reagent (WR) was prepared by mixing Reagent
A with Reagent B (50A:1B) to form a clear-green WR solution.

A 96-well plate

(Corning) was prepared for sample analysis by transferring 25 µL of each standard and
sample into separate wells in triplicate before adding 200 µL of the working reagent to
each well. The plate was gently shaken on a shaker plate (IKA® Works) for 30 seconds
before being placed in an incubator at 37°C for 30 minutes. At the end of incubation, the
plate was cooled for 10 minutes at room temperature. The absorbance values were
measured at a wavelength of 562 nm on an MRX® Revelation absorbance microplate
reader (DYNEX Technologies, Chantilly, VA). A standard curve was constructed by
plotting the average blank readings for each BSA standard against its concentration in
µg/mL.

Linear regression was performed on the standard curve and was used to

determine the protein concentration for each sample. This data was used to normalize
results from the alkaline phosphatase and extracellular calcium assays.
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Table 3 BSA dilutants for the standard curve
Plate Well
A
B
C
D
E
F
G
H
I

Diluent Volume
0
125
325
175
325
325
325
400
400

BSA volume & source
300 µL stock
375 µL stock
325 µL stock
175 µL from B
325 µL from C
325 µL from E
325 µL from F
100 µL from G
0

Final conc.
2000 µg/mL
1500 µg/mL
1000 µg/mL
750 µg/mL
500 µg/mL
250 µg/mL
125 µg/mL
25 µg/mL
0 (Blank)

Alkaline Phosphatase
The alkaline phosphatase content of each sample was determined according to
manufacturer protocol from Kit #104 (Sigma). A diluted p-nitrophenol (Sigma) standard
solution was formed by diluting p-nitrophenol in 0.02 N NaOH (Fisher Scientific). A
standard curve was generated using the dilution scheme displayed in Table 4. The
diluted p-nitrophenol samples were pipetted in triplicate in 200 µL quantities into a 96well plate (Corning) in order to generate a standard curve. The absorbance was read at
410 nm and the standard curve was determined by plotting absorbance versus ALP
activity. Linear regression was performed and the equation used to determine the ALP
activity in the samples. A working reagent was prepared by adding phosphatase substrate
solution and alkaline buffer solution 1:1 (both from Sigma). The working reagent was
added to 18 wells in a 24-well plate (Corning) in 500 µL quantities and allowed to
incubate at 37°C for 15 minutes. Cell lysates from the post-study testing plates were
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added in 100 µL quantities to separate wells containing the working reagent. A volume
in the amount of 100 µL of deionized water was added to the control well. The plates
were mixed on an orbital IKA® shaker (IKA® Works) for 30 seconds before being placed
in an incubator for 30 minutes at 37°C. The reaction was stopped by adding 1.5 mL of
0.25 N NaOH (Fisher Scientific) and mixing for 30 seconds on an orbital IKA® shaker.
The contents were transferred in triplicate in 200 µL quantities to a 96-well plate
(Corning).

The absorbance was measured at 410 nm using a MRX® Revelation

absorbance microplate reader. The concentration of each sample was determined by
using the quadratic equation from the standard curve. The ALP activity was normalized
with the total intracellular protein content. The basis of this assay is that a yellow colored
p-nitrophenol product is generated as ALP hydrolizes the p-nitrophenol phosphate in an
alkaline cell lysate.

Table 4 Dilution scheme for alkaline phosphatase standard curve
Tube #
1
2
3
4
5
6

Diluted p-nitrophenol solution
(mL)
1
2
4
6
8
10
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0.02N NaOH
(mL)
10
9
7
5
3
1

Extracellular Calcium
The remaining bone fragments and cell lysates were reserved to determine the
extracellular calcium content. A 6 N HCl sample solution was composed by transferring
the remaining contents of each sample well to individual glass test tubes (VWR
International, West Chester, PA) and adding 1 mL of ULTREX® II Ultrapure 12 N HCl
(J.T. Baker, Phillipsburg, NJ). The tubes were placed in I-CHEM™ glass bottles (Chase
Scientific Glass, Rockwood, TN) that contained 20 mL of 6 N HCl. The glass bottles
were sealed with Teflon®-lined lids and placed in a water bath. After bringing the water
to a boil, samples were heated for an additional 6 hours in order dissolve the bone
fragments. After all the samples were dissolved, each test tube was placed under nitrogen
gas flow in order to evaporate the supernatant. A precipitate remained in the bottom of
each test tube. One mL of Ultrapure 0.01 N HCl was added to each test tube to bring the
dried precipitate into solution.

Each sample was vortexed and transferred to 1.5

microcentrifuge tubes (VWR International, West Chester, PA) and frozen at -20°C. After
thawing the samples, 1.98 mL of an atomic absorption matrix solution was added to 0.02
mL of sample to eliminate chemical interference from phosphorus. The matrix solution
consisted of 0.3 N Ultrapure HCl and 0.5% (w/v) lanthanum oxide (Alfa Aesar, Ward
Hill, MA). Standards of 5, 15, and 30 µg/mL of Ca2+ were prepared from a calcium
reference solution (Fisher Scientific) and used to calibrate the Perkin Elmer 3030 atomic
absorption flame spectrophotometer (Perkin Elmer Instruments, Wellesley, MA). The
samples were run in triplicate on the same piece of equipment. The total extracellular
calcium was normalized with the intracellular protein content. The basis of this assay is
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that the calcium ions are atomized when heated by a flame. The ions are reduced to
unexcited, ground state atoms which absorb light at a wavelength of 422.7 nm (specific
for calcium).

Statistical Analysis
All quantitative assays were executed in triplicate.

Statistical analysis was

performed using SAS® System 9.1 statistical software (SAS Institute Inc., Cary, NC,
USA). The Least Squares Mean (LSMEANS) method was used for all quantitative
assays to determine the effects of the medium on the cellular activity of D1 cells seeded
on DBM. Values are represented by a standard error of mean (SEM) of n = 3. A
significance level of p = 0.05 was employed for all comparisons.
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In Vitro Evaluation of DBM
The final phase of this research was to examine the effects of partially
demineralized bone fragments and completely demineralized fragments on cellular
activity over 36 days. An evaluation of the cellular bone fragments was conducted to
determine the differences of cellular activity over time for each type of bone fragment.

Bone Matrix Preparation
A modified version of Urist’s protocol [13] was used to defat and demineralize
bovine bone. Diaphyseal cortical sections of bovine femurs were obtained from freshly
slaughtered cows from the Snow Creek Meat Processing Facility (Seneca, SC) for the
final study. The cow carcasses were stored at approximately 2.2ºC for 21-28 days before
the femurs were removed. Three femurs were obtained from Snow Creek to ensure that
bone was obtained from at least two cows.

The bone was transferred on ice and

immediately placed in a -80ºC freezer. After freezing, tissue was removed from the
diaphyseal section of the femurs and then frozen at -80ºC. The bone was sectioned with a
band saw (Delta) and cut into pieces approximately 2 cm x 2 cm x 2 cm and then refrozen
at -80ºC. The bone was sectioned into pieces 1 x 1 x 1 cm with a dremel (Dremel,
Racine, WI). The bone was then placed in a rotor-speed mill (Fritsch, Idar-Oberstein,
Germany) with a sieve insert of 2 mm. Approximately 35 mL of ground cortical bone
was collected from the three femurs for defatting and demineralization.
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Bone fragments were placed in a glass bottle along with a defatting solution
which consisted of a 3:1 volume of chloroform/methanol solution (90 mL of chloroform
(Acros, NJ) and 30 mL of methanol (Fisher Scientific)). The glass bottle was sealed with
a top and the contents were stirred at 4ºC for two hours. The spent liquid was removed
and an additional 120 mL of fresh defatting solution was added to the glass bottle and the
process was performed a second time. After the second removal of the defatting solution,
the bone fragments were washed in one volume (40 mL) of 100% ethanol for 30 minutes
at 4ºC, the ethanol was removed, and the fragments were placed in a clean glass bottle
and stored at 4ºC for approximately 9 hours.
The bone fragments were demineralized in ten volumes of 0.5 N HCl (350 mL for
80 minutes and 250 mL for the remaining 120 minutes) (Fisher Scientific) at room
temperature. The solution was stirred continuously in 40 minute intervals. Following
each 40 minute time period, a calcium oxalate test was performed and a visual analysis
by stereomicroscopy was conducted to determine the end point of demineralization.
After each acid cycle, 5 mL of spent HCl was combined with 5 mL of 5% (v/v)
ammonium hydroxide and 5 mL of 5% (v/v) ammonium oxalate (both from Fisher
Scientific) to chemically determine when bone fragments were completely demineralized.
Stereomicroscopy of the samples was performed at the end of each acid cycle as
described previously. Partially demineralized bone fragments were obtained following
two 40 minute cycles, and completely demineralized bone fragments were obtained after
200 minutes in the demineralization solution.
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A negative control (NDBM) was prepared by adding approximately 6 mL of
CDBM to 40 mL of guanidine hydrochloride (GnHCl) in 50 mM Tris buffer (pH 7.4)
(both from Sigma) to inactivate the osteoinductive proteins. The solution was stirred at
4ºC for 16 hours followed by two rinses in distilled water at room temperature.
The activity of the osteoinductive proteins in the PDBM and CDBM fragments
was preserved by lypholizing the fragments in a Labanco Lyph-Lock 6 freeze dryer
(Labanco Corporation, Kansas City, Missouri). Before lypholization, fragments were
stored at -20ºC for 30 minutes.

The bone fragments were then sterilized at room

temperature during a 12-hour ethylene oxide (EtO) infiltration cycle in an AN74i
sterilization chamber (Andersen Products), and degassed for two hours in the same
chamber. The samples were placed in a dessicator for 152 hours under vacuum (500 mm
Hg).

Cell Seeding
One day prior to cell seeding, the sterilized bone fragments underwent a
conditioning process in sterile 50 mL centrifuge tubes to ensure that all residual HCl was
removed.

The fragments were washed twice in 10 minute intervals in sterile PBS

(Sigma), then immediately rinsed five times (30 minutes per rinse), and then rinsed for
12-hours in α-MEM-C, as described previously.
Fresh α-MEM-C was added to each set of bone fragments after the conditioning
cycle was completed. The bone fragments were transferred in 0.1 mL quantities to well
plates with modified EtO sterilized pipets, as portrayed in Figure 3. One mL of fresh α-

35

MEM-C was then added to each well. The well plates were placed in a sterile hood
overnight. Four time points were selected and four plates for each time point were
prepared, resulting in a total of 16 ultra-low attachment plates (Corning).
The spent media was aspirated from the well plates and replaced with 1 mL of αMEM-M on the day of cell seeding, as shown in Figure 3. Multipotent mouse marrow
stromal cells (D1’s) (#CRL-12424, ATCC) of passage 32 were seeded into each well at a
density of 3 x 105 cells/well.

The negative acellular control group received bone

fragments and medium, but no cells.

All wells were placed in an incubator under

standard conditions of 37ºC and 5% CO2 on an orbital shaker (IKA® Works) set in
motion at approximately 50 rpm. The day of cell seeding was denoted as Day 0 of the
study. The medium was changed on Days 2, 4, 6, 8, 10, 12, 13, 15, 16, 18, 20, 22, 24, 26,
28, 30, 32, 34, and 36 during the 36-day study.
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D1

acellular

PDBM

α-MEM-M
PDBM

α-MEM-C
NDBM

α-MEM-C

1 plate/time point for gene expression
1 plate/time point use for BCA, ALP, then calcium assays
1 Day 24 plate used for lactic acid/glucose and Alamar Blue™ for all time
points
Total of 8 plates prepared with this layout

D1

acellular

PDBM
α-MEM-M

PDBM
α-MEM-C

NDBM
α-MEM-C

1 plate/time point for cell viability
1 plate/time point for histology
Total of 8 plates prepared with this layout
α-MEM-M and bone fragments

Figure 3 Plate set-ups for the level of demineralization study

37

Qualitative Microscopy
Cell Viability
A LIVE/DEAD® Viability/Cytotoxicity kit (Molecular Probes, Eugene, OR) was
used, as described earlier, to analyze the cells on the bone fragments and to determine if
the medium conditions affected the viability of the cells on Days 4, 13, 24 and 36.

Histology
Samples for histological analysis were processed on Days 4, 13, 24, and 36. At
the desired time point, each well in the specified plate was rinsed twice with sterile PBS
(Sigma), and 1 mL of 10% neutral buffered formalin was added to each well. The plate
was stored at 4°C for 24 hours. A Technovit 7100 GMA embedding kit (EBSciences,
East Granby, Connecticut) was used to prepare and embed the bone samples. Samples
were pre-infiltrated with increasing concentrations of GMA as listed in Table 5. Samples
were then infiltrated for 24 hours with mild agitation at 22°C with Solution A, which
consisted of a ratio of 100 mL of GMA monomer for every gram of Hardener I.
Following infiltration, fragments were dried and placed into separate molds in a molding
tray. An embedding solution consisting of 15 parts of Solution A and 1 part of Hardener
II was mixed for one minute and immediately used to embed the bone fragments.
Samples were stored in a dessicator at room temperature until sectioning.

Eight

micrometer sections were obtained using a RM2155 rotary microtome (Leica). Sections
were stained with hemotoxylin and eosin (H&E), to study the cellular attachment on the
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bone, and von Kossa, to analyze the mineralization of the bone. Protocols can be found
in Appendices A and B. Images were captured using an Axiovert 135 microscope
(Zeiss), a ProgRes™ C10Plus digital color camera and ProgRes Capture Basic 1.2 software
(both from Jenoptik). The images were analyzed with Image-Pro Plus 5.1 Software
(Media Cybernetics).

Table 5 Pre-infiltration series
Step
1
2
3
4
5
6
7
8
9
10
11

% of GMA
monomer
5%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%

39

Time

Temperature

1 hour
1 hour
1 hour
1 hour
1 hour
1 hour
1 hour
1 hour
1 hour
1 hour
1 hour

Room
Room
Room
Room
Room
Room
Room
Room
Room
Room
Room

Real-Time Quantitative Testing

Metabolic Activity

Lactic Acid and Glucose Levels
The lactic acid and glucose levels were analyzed at every medium change, which
occurred on Days 2, 4, 6, 8, 10, 12, 13, 15, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
Before the medium was aspirated, 400 µL of spent medium was removed from each well
and analyzed using a YSI 2700 SELECT™ biochemistry analyzer (YSI, Yellow Springs,
OH). The YSI analyzer was used, as described previously, to analyze lactic acid and
glucose levels in the medium.

Alamar Blue™
The metabolic activity of the cells seeded on the demineralized bone fragments
was assessed on Days 4, 13, 24 and 36 using an Alamar Blue™ dye (BioSource
International), as described previously. Briefly, after aliquots were removed for lactic
acid and glucose monitoring, spent media was removed and replaced with 1 mL of αMEM-M and incubated for 4 hours. The dye was added at this time and allowed to
incubate for an additional 3 hours. Medium aliquots were transferred in triplicate to a
clear 96-well plate (Corning). The fluorescence values were read on a SpectraMax®
Gemini EM Dual scanning spectrofluorometer (Molecular Devices).

The remaining

medium in the 24-well plates was aspirated and replaced with 1 mL of fresh medium.
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Post-Study Quantitative Testing
The 24-well plate specified for post-study quantitative testing at each time point
was rinsed twice in sterile PBS (Sigma). Following the rinse, 1 mL of 0.5% Triton-X
(Fisher Scientific) in PBS (Sigma) was added to lyse the cells. The plates were frozen at
-80°C until the plates for all time points were collected. The plates underwent three
freeze/thaw cycles to lyse and release the proteins. At this time, samples were removed
for alkaline phosphatase and intracellular protein assays. The remaining cell lysate and
bone fragments were used for the extracellular calcium assay.

Intracellular Protein
The intracellular protein content was determined using a BCA Protein Assay
Reagent Kit (Pierce Biotechnology) and following manufacturer protocol. The assay was
performed as previously described. This data was used to normalize results from alkaline
phosphatase and extracellular calcium assays.

Alkaline Phosphatase
The alkaline phosphatase content of each sample was determined following
manufacturer protocol from Kit #104 (Sigma). The ALP activity values were normalized
using the total intracellular protein content.
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Extracellular Calcium
The remaining bone fragments and cell lysates were used to determine the
extracellular calcium content.

Samples were prepared for analysis as previously

described. After thawing the samples, PDBM samples were diluted 1:10 with the atomic
absorption matrix solution and CDBM and NDBM samples were diluted 1:100 with the
same solution. The matrix solution consisted of 0.3 N Ultrapure HCl and 0.5% (w/v)
lanthanum oxide (Alfa Aesar, Ward Hill, MA). Samples were analyzed with a Perkin
Elmer 3030 atomic absorption flame spectrophotometer (Perkin Elmer) as described
previously. The total extracellular calcium was normalized with the intracellular protein
content.

Gene Expression
The expression of osteoblast-specific genes was monitored by performing realtime reverse transcription-polymerase chain reaction (RT-PCR) on Days 4, 24, and 36.
Ribonucleic acid (RNA) was isolated from the tissue culture and the quantity and quality
of each sample was analyzed. Primers and reaction parameters were optimized before
real-time RT-PCR testing was completed on all samples.

RNA Isolation
RNA was isolated from the culture on Days 4, 13, 24 and 36 by following
manufacturer protocol and using an RNeasy® Mini Kit (Qiagen, Valencia, CA). The
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fragments in the specified 24-well plate were rinsed twice in sterile PBS (Sigma). The
cell membranes were lysed by the addition of 600 µL of β-Mercapthoethanol (β- ME)
(Sigma) and Buffer RLT solution. The lysis solution was composed of 10 µL of β- ME
per 1 mL of Buffer RLT. After remaining at room temperature for ten minutes, the
samples were homogenized by placing the lysate from each sample onto a QIAshredder
column placed in a 2 mL collection tube. The tubes were centrifuged for 2 minutes at
13,000 rpm. One volume (600 µL) of 70% ethanol was added to the homogenized
lysates in each tube. A volume of 700 µL of the sample was deposited on an RNeasy
mini column placed in a 2 mL collection tube and centrifuged for 15 seconds at 13,000
rpm. The flow-through was discarded before the remaining lysate (500 µL) was placed
into the same column and the centrifugation step was repeated. After discarding the
flow-through, 350 µL of Buffer RW1 was added to the RNeasy column, followed by
centrifugation at 13,000 rpm for 15 seconds. DNase treatment was performed on the
column using an RNase-free DNase Set (Qiagen), after discarding the flow-through from
the first wash step with Buffer RW1. Eighty microliters of the DNase treatment (70 µL
of RDD buffer and 10 µL of DNase I stock solution) was placed on the columns and
remained on the bench top for 15 minutes. Another 350 µL of Buffer RW1 was added to
the RNeasy column, followed by centrifugation at 13,000 rpm for 15 seconds. RNA
isolation continued as the flow-through and collection tubes were discarded. The RNeasy
column was transferred to a new 2 mL collection tube and 500 µL of Buffer RPE was
added to the column. The tubes were centrifuged for 15 seconds at 13,000 rpm to wash
the columns and the flow-through was discarded. An additional 500 µL of Buffer RPE
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was added to the column and each sample was centrifuged for 2 minutes at 13,000 rpm to
dry the silica-gel membrane in the column. The columns were transferred to new 1.5 mL
collection tubes in order to collect the RNA from the column. The first elution step was
performed by adding 50 µL of RNase free water to the column and centrifuging the
column for one minute at 13,000 rpm. The elution step was repeated so that 100 µL of
RNA sample was collected for each replicate and fragment type from the cell culture. All
samples were stored at -80°C immediately after the elution phase.

RNA Analysis
The purity and concentration of each RNA sample was determined using an RNA
6000 Nano Assay Kit (Agilent Technologies, Palo Alto, CA) and following the
manufacturer protocol. Twelve RNA samples were tested at a time. The RNA samples
and the RNA 6000 ladder (Agilent Technologies) were thawed on ice, while the
remainder of the reagents were thawed at room temperature for 30 minutes. A gel mix
was prepared by placing 550 µL of RNA 6000 Nano gel matrix onto a spin filter and
centrifuging it for 10 minutes at 4000 rpm. The gel was then aliquoted into tubes in 65
µL quantities. A gel-dye mix was made by adding 1 µL of RNA 6000 Nano dye
concentrate to 65 µL of gel. The tube was centrifuged for 10 minutes at 14,000 rpm. A
RNA Nano chip was placed onto the Chip Priming Station and 9 µL of the gel dye matrix
was pipetted into a specific well on the chip. The gel-dye mix was distributed throughout
the LabChip® by pressurizing it for 30 seconds using a Chip Priming Station. Nine µL of
the gel-dye mix was then added to two specific wells on the chip. The RNA 6000 Nano
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Marker was added by pipetting 5 µL of the reagent into each of the 12 sample wells and a
ladder well. A volume of 2 µL of the ladder was heat denatured for 2 minutes at 70°C
before 1 µL of the ladder was added to the well marked ladder. RNA samples were
added to each well in 1 µL quantities. The LabChip® was then vortexed for 1 minute at
2400 rpm and immediately placed in an Agilent 2100 Bioanalyzer (Agilent
Technologies).

Using Agilent 2100 Expert Software (Agilent Technologies), the

Eukaryote Total RNA Nano program was used to calculate the RNA concentration and
purity of each sample. This analysis was repeated for all RNA samples. All samples
were placed back at -80°C until real-time RT-PCR was performed.

Primer Design
Three genes were selected to monitor the differentiation of the mouse stromal
cells to the osteoblast lineage: runt-related transcription factor 2 (Runx2), bone
sialoprotein (BSP), and osteocalcin (OCN).

The gene β-actin was used as the

housekeeping gene. Runx2 regulates extracellular bone matrix gene expression including
osteocalcin, bone sialoprotein, osteopontin, and type I collagen [54, 55]. Therefore,
Runx2 is expressed in pre-osteoblasts [13]. BSP is restricted to cells that have secreted
and are actively mineralizing type I collagen; therefore, it is only expressed in newly
formed mineralizing osteoblasts [13].

OCN is synthesized by osteoblasts and is

considered a late marker for differentiation of cells into osteoblasts.
Target primers were designed using the method presented in Appendix C. The
selected primers (Table 6) were ordered from Integrated DNA Technologies (IDT,
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Coralville, IA), and were received in a lypholized powder form. The primers were
resuspended in RNase-free water at a concentration of 100 µM, aliquoted into 1.5 mL
nuclease-free tubes and stored at -20°C.

46

47

Accession
Number
NM007393
AF10284
BC045143
BC101948

Target Gene

β-actin

Runx2

Bone Sialoprotein

Osteocalcin
CCAAGCAGGAGGGCAATAAG

TACGGAGCAGAGACCACACC

GACTTCTGCCTCTGGCCTTC

CCCTGAACCCTAAGGCCAAC

Forward primer (5'-3')

Reverse Primer (5'-3')

GTCACAAGCAGGGTCAAGCTC

CTTCTTCCTCGTCGCTTTCC

GGTAGTGCATTCGTGGGTTG

GCATACAGGGACAGCACAGC

Table 6 Primers for real-time RT-PCR

119

121

142

105

Amplicon
Size (bp)

Real-Time RT-PCR
A QuantiTect® SYBR® Green RT-PCR Kit (QIAGEN) was used to determine the
relative gene expression levels in the RNA samples. The manufacturer’s protocol was
followed for performing the real-time RT-PCR reactions on a Rotor-Gene™ RG-3000
centrifugal thermal cycler (Corbett Research, Australia) using a 36 well rotor. The
QuantiTect® RT-PCR Master Mix, RNase-free water, primers, and RNA samples were
thawed on ice and then combined with the QuantiTect® RT Mix (Figure 6). Stock primer
solutions were diluted to concentrations of 20 µM by the addition of RNase-free water
and added to the PCR solutions so that the final concentration of primer in each reaction
was 0.4 µM. The reaction components were pipetted in specific volumes into 0.2 mL
RT-PCR reaction tubes (Fisher Scientific) on ice (Figure 7).

Non-template control

solutions were prepared without RNA samples and –RT control solutions were made
without the QuantiTect® RT Mix. RNA samples were diluted either 1:2 or 1:4 with
RNase-free water to provide a 20 ng sample of RNA so that a volume of RNA greater
than 0.8 µL was added for each reaction. RNase-free water was added all PCR reaction
tubes to bring the final reaction volume to 50 µL. The cycler was set up as indicated in
the QuantiTect® SYBR® Green RT-PCR Kit manufacturer handbook and included a
reverse transcription step, an activation step, and either 35 or 40 four-step cycles (35 was
suitable for most reactions but one set of data needed a 40 step cycle) that included
denaturation, annealing, and extension (Table 8).
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Table 7 Real-time RT-PCR reaction components
Reagent

Volume per
reaction (µL)

Final
concentration

QuantiTect® RTPCR Master Mix

25

1x

QuantiTect® RTMix

0.5

0.5 µL/reaction

Forward primer

1

0.4 µM

Reverse primer
Template RNA
RNase-free water

1
Variable
Variable

0.4 µM
20 ng/reaction
--

Table 8 Real-time RT-PCR cycler conditions
Step
Reverse
Transcription
PCR Initial
Activation
4-Step Cycle (x 35)
Denaturation
Annealing
Extension #1
Extension #2

Time

Temperature

30 minutes

50°C

15 minutes

95°C

15 seconds
30 seconds
30 seconds
15 seconds

94°C
50°C
72°C
75°C

The cycle number in the exponential phase of amplification at a specific
threshold, CT, was recorded for each sample reaction.
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Amplification Efficiency Determination
The comparative C T analysis method is only valid if the difference between the
amplification efficiency of the sample amplification and the efficiency amplification of βactin is less than 5%. To determine if this method was viable for the data set, real-time
RT-PCR reactions were performed in triplicate for each target gene using the following
serial dilution series: 20 ng, 2.0 ng, and 0.2 ng. The reactions were prepared and carried
out as described previously. RNA from a Day 36 CDBM sample was used for this
analysis. Average CT values for each target gene were plotted versus LOG10 of the RNA
quantity. Linear regression was performed on each target gene graph separately and the
amplification efficiency was determined by:
E=10(-1/slope) – 1

(7.1)

Statistical Analysis
All quantitative assays were executed in triplicate.

Statistical analysis was

performed using SAS® System 9.1 statistical software (SAS Institute Inc.). The Least
Squares Mean (LSMEANS) method was used to determine the effects of the level of
demineralization on the cellular activity over time of cells seeded on DBM in all
quantitative assays. Values are represented by a standard error of mean (SEM) for a
sample number, n, of 3.

A significance level of p = 0.05 was employed for all

comparisons.
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RESULTS

Evaluation of Media Cocktails

Bone Matrix Preparation
Stereomicroscope digital images of bone fragments were acquired after each forty
minute HCl demineralization cycle (Figure 4).

1000 µm

1000 µm
A

B

Figure 4 Stereomicroscope images
Images obtained of bone fragments that were demineralized for 80 minutes.

The bone fragments had bright areas of mineralization even after 80 minutes of
demineralization. Demineralized regions surrounding the mineralized areas appeared
glassy. As a result, PDBM fragments were acquired after 80 minutes of demineralization
in the 0.5 N HCL.
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Cell Seeding
During the conditioning process, the medium immediately turned orange
following the first bone fragment wash and gradually changed to yellow as the thirty
minutes progressed. By the end of the last step of the conditioning sequence, the medium
remained pink, indicating that no residual acid remained on the bone fragments.

Qualitative Microscopy

Cell Viability
Representative fluorescence micrographs display the viability of D1 cells on the
demineralized bone fragments (Figure 5). The fragments in each image have irregular
shapes and vary in size.

The cells attached to the DBM fragments in all culture

conditions by Day 4 of the study (Figure 5). A larger number of live cells were visible on
the DBM fragments in the medium containing osteogenic supplements (OSTEO) on Day
13 than on the DBM fragments in the other conditions. It appeared that the number of
cells on the DBM in the medium without osteogenic supplements (NOSTEO) and on the
negative control fragments decreased between Day 13 and Day 4. The number of viable
cells appeared to decrease in all media by Day 24 of the study. As time increased, it
seemed that the number of dead cells remaining on the bone fragments increased. The
ratio of live cells to dead cells was large at all time points for all three conditions.
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Figure 5 Cell viability
Fluorescence micrographs demonstrating cellular attachment and coverage of D1 cells for
three media and DBM conditions.
(A) OSTEO Day 4
(B) NOSTEO Day 4
(C) CONTROL Day 4
(D) OSTEO Day 13 (E) NOSTEO Day 13 (F) CONTROL Day 13
(G) OSTEO Day 24 (H) NOSTEO Day 24 (I) CONTROL Day 24
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Histology
H&E staining was performed to illustrate cell distribution on the DBM fragments
and von Kossa staining was performed to assess mineralized areas of the bone fragments.
Light micrographs portray the staining results (Figure 6-7). Light micrographs of the
samples stained with H&E showed cellular attachment on the surface of bone fragments
from all three conditions. The images displayed in Figure 6 are representative of images
obtained for each specific condition at the specified time point. On Day 4, multiple
layers of cells were attached to the outer surface of the NOSTEO fragments and a single
layer of cells attached to fragments cultured in osteogenic supplemented media and the
control fragments.

The number of cell layers was uniform for the control and the

fragments cultured in osteogenic supplements on Day 4, while the number of layers on
the surface of NOSTEO fragments varied greatly between samples. Cellular infiltration
was evident on Day 4 for both sample DBM fragments. Results from the H&E staining
did not suggest that the configuration and quantity of cells on OSTEO fragments was
significantly different from the configuration and quantity on NOSTEO fragments
between Days 4 and 13. Cellular infiltration was evident on the control fragments on
Day 13. The thickest layers of cells attached to the bone surface and the greatest degree
of cellular infiltration into the bone for all cultures was observed on Day 24.
Light microscopy of PDBM fragments revealed mineralized portions of the tissue
(Figure 7). Day 4 fragments cultured with osteogenic supplements consistently contained
centrally located mineralized areas. Day 4 NOSTEO and control fragments contained
variable amounts of mineralization. Most of the control fragments, and the fragments
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cultured in non-osteogenic supplemented media, contained only small areas of
mineralization, dispersed throughout the sample, although a small number of fragments
did contain larger, centrally located mineralized areas. Experimental samples from Day
13 contained regions of mineralization dispersed through the tissue sample, but these
areas were smaller than the mineralized areas observed on Day 4 in the OSTEO
fragments. Select Day 13 OSTEO fragments contained larger areas of mineralized tissue
in the center of the bone, while many of the fragments still contained only smaller areas
of mineralization. The number of cells on the surface of the PDBM fragments cultured in
osteogenic supplemented media (OSTEO) containing large mineralized regions was
greater than on the OSTEO fragments containing only small mineralized areas on Day
13. Fragments cultured in media without osteogenic supplements (NOSTEO) showed
good cellular infiltration but minimal mineralized areas on Day 24. PDBM control
fragments contained areas of mineralization on the edges, with only small areas within
the fragment on Day 24. Day 24 OSTEO fragments were similar to Day 4 fragments,
except the Day 24 samples also contained select, small mineralized areas.
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Figure 6 H&E light micrographs
Light micrographs showing attachment and distribution of D1 cells. Images obtained
after H&E staining.
Pink: DBM Dark purple: nuclei Light purple: cytoplasm, extracellular matrix.
(A) OSTEO Day 4
(B) NOSTEO Day 4
(C) CONTROL Day 4
(D) OSTEO Day 13 (E) NOSTEO Day 13 (F) CONTROL Day 13
(G) OSTEO Day 24 (H) NOSTEO Day 24 (I) CONTROL Day 24
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Figure 7 von Kossa light micrographs
Light micrographs obtained after von Kossa staining with eosin counterstain.
Light pink: DBM
Dark pink: cells
Black: mineralized matrix
(A) OSTEO Day 4
(B) NOSTEO Day 4
(C) CONTROL Day 4
(D) OSTEO Day 13 (E) NOSTEO Day 13 (F) CONTROL Day 13
(G) OSTEO Day 24 (H) NOSTEO Day 24 (I) CONTROL Day 24
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Real-Time Quantitative Testing
Metabolic Activity
Lactic Acid and Glucose Levels
The cumulative lactic acid production for each media condition increased over
time (Figure 8). The level of lactic acid production of OSTEO fragments (cultured in
osteogenic supplemented media) on Days 4 and 24 was significantly higher (p < 0.05)
than that of the negative control cultures and significantly higher (p < 0.05) than that in
NOSTEO fragments (cultured in media lacking osteogenic supplements) cultures on
Days 13 and 24.
The total glucose consumption increased over time for each medium and fragment
condition (Figure 9). The PDBM with osteogenic supplemented medium (OSTEO) had
significantly lower (p < 0.05) levels of total glucose than the negative control on Days 4,
13, and 24. A significant difference in total glucose consumption was not observed
between OSTEO and NOSTEO cellular cultures or NOSTEO and control cellular
cultures at any time point.
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Total Accumulation of Lactic Acid

Total lactic acid produced (g/L)
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6

CONTROL

4
2
0
Day 4

Day 13

Day 24

Time

Figure 8 Cumulative lactic acid production
Total lactic acid production as a function of culture day. Each data point represents the
mean of three values, and error bars denote SEM.
Asterisks denote statistical differences (p<0.05) in lactic acid levels with respect to time.
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Total Glucose Consumption

Total Glucose Consumption, g/L
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Figure 9 Cumulative glucose consumption
Cumulative glucose consumption as a function of culture day. Each data point represents
the mean of three values, and error bars denote SEM.
Asterisks denote statistical differences (p<0.05) in glucose level with respect to time.

Alamar Blue™
The Alamar Blue™ assay results indicated that the metabolic activity was not
significantly different between the two experimental PDBM mediums on Days 4 and 13
(Figure 10). On Day 24, the medium containing no osteogenic supplements (NOSTEO)
had a significantly higher (p < 0.05) metabolic activity level than the medium containing
the osteogenic supplements (OSTEO). The metabolic activity of the control samples on
Day 13 was significantly larger (p < 0.05) than the medium without osteogenic
supplements. No significant differences existed on Day 4 between any of the cultures.
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Metabolic Activity via Alamar Blue,
relative fluoresence units

Metabolic Activity
16,000

*

14,000

*

12,000
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CONTROL

4,000
2,000
0
Day 4

Day 13

Day 24

Time point

Figure 10 Metabolic activity via Alamar Blue™
Metabolic activity as a function of culture day for each fragment type. Each data point
represents the mean of three values, and error bars denote SEM.
Asterisks denotes statistical differences (p<0.05) in metabolic activity with respect to
time.

Post-Study Quantitative Testing
Intracellular Protein
No significant differences in the protein levels were detected between the medium
conditions at each time point observed (Figure 11). A single condition did not have a
significantly higher level of intracellular protein content (p < 0.05) at any of the three
time points. The intracellular protein contents on the control and the fragments cultured
in osteogenic supplemented media increased from Day 4 to Day 13, then decreased on
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Day 24. The protein levels measured in the NOSTEO (no osteogenic supplements)
systems increased over the observed time period.

Intracellular Protein
500
Intracellular Protein, ug

450
400
350
300

OSTEO

250

NOSTEO

200

CONTROL
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100
50
0
Day 4

Day 13

Day 24

Time Point

Figure 11 Intracellular Protein
Intracellular protein level as a function of time for each fragment type. Each data point
represents the mean of three values, and error bars denote SEM.
Asterisks denote a statistical difference (p<0.05) in intracellular protein level with respect
to time.

Alkaline Phosphatase
Overall, the ALP activity in the three cultures increased between Days 4 and 24,
although the activity decreased between Days 4 and 13 for the medium with osteogenic
supplements, before increasing on Day 24 (Figure 12). The medium containing
osteogenic supplements (OSTEO) had significantly lower ALP levels on Day 24 than
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both the negative control and the samples cultured in the medium without osteogenic
supplements (NOSTEO). OSTEO cultures had the highest level of ALP activity on Day
4, but then had the lowest levels on Days 13 and 24. Control fragments had the highest
ALP activity levels on Days 13 and 24.

ALP Activity, µmol/min/mg protein

Alkaline Phosphatase Acvitity
0.18

*

0.16
0.14

*

0.12
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NOSTEO

0.08

CONTROL

0.06
0.04
0.02
0
Day 4

Day 13

Day 24

Time Point

Figure 12 Alkaline phosphatase activity
ALP levels as a function of time for each fragment type. Each data point represents the
mean of three values, and error bars denote SEM.
*Asterisks denote a statistical difference (p<0.05) in ALP level with respect to time.

Extracellular Calcium
The level of extracellular calcium observed on Day 4 in the negative control
cultures was significantly higher (p < 0.05) than the level observed in the cultures with
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medium containing osteogenic supplements (OSTEO) (Figure 13). The extracellular
calcium content of the OSTEO cultures increased over the course of the study. The
highest level of observed extracellular content in both the NOSTEO and control cultures
occurred on Day 4 of the study. Both these conditions decreased on Day 13 and then
increased on Day 24. The observed extracellular calcium levels from the control and the
samples cultured without osteogenic supplements were lower on Day 24 than the initial
levels observed on Day 4.

Total Extracellular Calcium

Calcium, ug/mg protein
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Figure 13 Extracellular calcium
Extracellular calcium levels as a function of time for each fragment type. Each data point
represents the mean of three values, and error bars denote SEM.
Asterisks denote statistical differences (p<0.05) in extracellular calcium level with
respect to time.
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In Vitro Evaluation of DBM
Bone Matrix Preparation
Stereomicroscopic digital images were acquired of bone fragments Figure 14)
after each forty minute HCl cycle in order to determine the demineralization endpoint for
each sample group. The cumulative time of demineralization is displayed with each
image.

1000 µm

1000 µm
A

B

Figure 14 Stereomicroscope images of bone fragments
A) shows PDBM fragments after 80 minutes of demineralization. (B) CDBM fragments
after 200 minutes of demineralization.

Bright areas within the bone fragments in the stereomicroscope images signify
mineralized areas of the bone. Examination of bone fragments after 80 minutes, revealed
mineralized cores with outer, mineralized regions. These fragments were considered to
be partially demineralized and thus fragments were removed at this time and denoted
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PDBM. Mineralization was not evident after 200 minutes of demineralization. Thus,
CDBM fragments were collected at this time. The fragments displayed in Figure 14 are
representative of fragments obtained for each time point.

Cell Seeding
The media color was monitored during the conditioning process to ensure
any residual acid was removed from the bone before cell seeding. After the addition of
the medium to the bone fragments for the first wash, the medium changed from red to
orange to yellow over the course of the thirty minutes. By the end of the last step of the
conditioning sequence, the medium remained pink, indicating that no residual acid
remained on the bone fragments.

Qualitative Microscopy

Cell Viability
Fluorescence micrographs obtained after cytotoxicity testing demonstrate the
viability of D1 cells on the demineralized bone fragments (Figure 15). The micrographs
display select bone fragment size and shape irregularity; however, overall the fragments
were similar in size and shape. The fragments displayed in Figure 15 are representative
of fragments photographed in the micrographs obtained from other fragments within each
sample as well as each replicate for each fragment type.
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Cells readily attached to the PDBM and CDBM fragments by Day 4 of the study,
and did not attach to the bottom of the wells, as noted by the green fluorescence seen in
Figure 15. Cells attached to the NDBM at this time point but did not appear confluent
until Day 13. Dead cells were visible on Day 13 for all fragment conditions, as noted by
the red fluorescence on the bone fragments. The number of visible dead cells increased
over time for each fragment condition. Few cells remained on the NDBM by Day 36.
The surfaces of the bone fragments appeared to be fully covered on Day 4, Day 13, Day
24, and Day 36.
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Figure 15 Cell viability
Fluorescence micrographs demonstrating cellular attachment and coverage of three media
and DBM conditions.
Images obtained following LIVE/DEAD® Viability assay.
(A) PDBM Day 4
(B) CDBM Day 4
(C) NDBM Day 4
(D) PDBM Day 13 (E) CDBM Day 13
(F) NDBM Day 13
(G) PDBM Day 24 (H) CDBM Day 24 (I) NDBM Day 24
(J) PDBM Day 36
(K) CDBM Day 36 (L) NDBM Day 36
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Histology
H&E staining was performed to illustrate cell distribution on the DBM fragments
and von Kossa staining was performed to demonstrate mineralization of the DBM
fragments at each time point. Light micrographs portray the staining results for each type
of stain on the bone fragments (Figure 16-17). Images displayed are representative of the
fragments observed for each time point and fragment type.
H&E staining of Day 4 PDBM fragments portray a thin layer of cells attached to
the surface of the bone fragments. As time increased, the number of cells attached to the
outside of the PDBM increased. The level of cellular infiltration also increased over
time. The cells were most abundant on the outside and within the PDBM fragments on
Day 36. CDBM fragments had varying layers of cells on the outside of the bone
fragments on Day 4 and 13 with more consistent layers of cells present on Days 24 and
36. Cellular infiltration was observed on CDBM fragments on Days 24 and 36. The least
amount of cells was observed on and within the CDBM fragments on Days 4 and 13
while the most abundant number of cells was observed on Days 24 and 36. The layer of
cells on the outside of NDBM fragments was similar to the layers found on Day 4 PDBM
fragments and Day 13 CDBM fragments. Cellular infiltration of the NDBM fragments
was observed on Day 13 and an increase of cellular infiltration was observed on each
subsequent time point. Cellular infiltration was not as abundant within NDBM fragments
as it was with PDBM and CDBM fragments over the course of the study. The cellular
infiltration within PDBM fragments on Day 24 was similar to the cellular infiltration of
CDBM fragments on Day 36.
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On Days 4, 13, and 24, a thicker layer of cells existed on the surface of CDBM
fragments than PDBM and NDBM fragments. Day 4 PDBM fragments had cellular
infiltration while CDBM and NDBM fragments did not. Overall, the thickest layer of
cells and the greatest amount of infiltration existed on the outside of PDBM fragments on
Day 36. NDBM fragments and Day 4 PDBM fragments had the thinnest layers of cells
during the study. NDBM fragments contained the least amount of infiltration at all time
points observed in this study.
Von Kossa staining of Day 4 samples revealed that almost all PDBM fragments
had similar, large mineralized centers.
regions with smooth edges.

The mineralized areas appeared as circular

The fragments without a solid center had numerous

mineralized areas. Day 13 images of PDBM were similar to those on Day 4. Small,
black specks were visible surrounding the mineralized core on Day 24, indicating the
presence of small mineralized areas outside the large mineralized center.

The

mineralized cores appeared to have irregular edges by Day 36. Small areas of black
within the tissue were also visible. Most of the CDBM fragments on Day 4, observed
after von Kossa staining, lacked mineralized areas of bone.

A few of the CDBM

fragments had spots of mineralization indicating that not all of the fragments were
completely demineralized before cell culture was started. Day 13 CDBM fragments were
unchanged in appearance from Day 4. By Day 24, slightly larger areas of mineralized
bone were visible than at previous time points. CDBM images obtained on Day 36 were
similar to images obtained on Day 24. Day 4 NDBM fragments were mainly void of
mineralized centers, where only a few fragments had small areas of mineralized tissue.
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Day 13 NDBM von Kossa images were largely similar to those taken at Day 4; however,
Day 24 and Day 36 images had a small number of tissue areas with mineralized spots.
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Figure 16 H&E light micrographs
Light micrographs obtained after H&E staining.
Pink: DBM Dark purple: nuclei Light purple: cytoplasm, extracellular matrix.
(A) PDBM Day 4
(B) CDBM Day 4
(C) NDBM Day 4
(D) PDBM Day 13 (E) CDBM Day 13
(F) NDBM Day 13
(G) PDBM Day 24 (H) CDBM Day 24 (I) NDBM Day 24
(J) PDBM Day 36
(K) CDBM Day 36 (L) NDBM Day 36
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Figure 17 Von Kossa light micrographs
Light micrographs obtained after von Kossa staining with eosin counterstain.
Light pink: DBM
Dark pink: cells
Black: mineralized matrix
(A) PDBM Day 4
(B) CDBM Day 4
(C) NDBM Day 4
(D) PDBM Day 13 (E) CDBM Day 13
(F) NDBM Day 13
(G) PDBM Day 24 (H) CDBM Day 24 (I) NDBM Day 24
(J) PDBM Day 36
(K) CDBM Day 36 (L) NDBM Day 36
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Real-Time Quantitative Testing

Metabolic Activity

Lactic Acid and Glucose Levels
The cumulative lactic acid production increased over time with respect to each
fragment type.

The level of total lactic acid accumulation for each fragment type

increased significantly (p < 0.05) with time. The accumulation of lactic acid for each
fragment type at each time point is displayed in Figure 18.

Accumulation of Lactic Acid
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Figure 18 Lactic acid accumulation
Cumulative lactic acid production as a function of culture day. Each data point
represents the mean of three values, and error bars denote the standard error of the mean
(SEM).
Asterisks denote statistical differences (p<0.05) in lactic acid levels with respect to time.
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The cumulative consumption of glucose increased over time with respect to each
fragment type . The total consumption of glucose increased significantly (p < 0.05) with
time for each fragment type. The accumulation for each fragment type at each time point
is displayed in Figure 19.
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Figure 19 Cumulative glucose consumption
Cumulative glucose consumption as a function of culture day. Each data point represents
the mean of three values, and error bars denote SEM.
Asterisks denote statistical differences (p<0.05) in lactic acid levels with respect to time.

Alamar Blue™
The determination of metabolic activity of the D1 cells seeded on bone fragments
indicates that, as time progressed, the cellular metabolic activity for each fragment type
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increased significantly (p < 0.05) at varying times (Figure 20).

Cells on all three

fragment types, PDBM, CDBM, and NDBM, demonstrated a decrease in metabolic
activity between Days 4 and 13, subsequently followed by an increase between Days 13
and 24. The measured metabolic activity of the cells loaded on the CDBM and NDBM
fragments continued to increase between Days 24 and 36 while the cells seeded on
PDBM fragments demonstrated a decrease in metabolic activity between these two time
points. The metabolic activity of the cells on the PDBM fragments changed significantly
(p < 0.05) between Day 4 and Day 13, Day 13 and Day 24, and in between Day 24 and
Day 36. Metabolic activity of cells on the CDBM fragments changed significantly (p <
0.05) between Day 4 and Day 36 as well as between Day 13 and Day 24.
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Metabolic Acvitity via Alamar Blue,
relative fluorescence units

Metabolic Activity
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Figure 20 Metabolic activity via Alamar Blue™
Metabolic activity as a function of culture day for each fragment type. Each data point
represents the mean of three values, and error bars denote SEM.
Asterisks denote statistical differences (p<0.05) in lactic acid levels with respect to time.

Post-Study Quantitative Testing

Intracellular Protein
The intracellular protein level of D1 cells increased over time when seeded on
PDBM, CDBM, and NDBM fragments (Figure 21).

PDBM and CDBM cultures

exhibited significant increases (p < 0.05) in protein level between Day 4 and Day 13 and
again between Day 24 and Day 36. Although the protein levels in the PDBM and CDBM
conditions decrease between Days 13 and 24, it was not a significant decrease (p > 0.05).
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The NDBM condition showed a significant increase in protein level between Day 4 and
Day 36 and between Day 13 and Day 36.

Intracellular Protein
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Figure 21 Intracellular protein
Intracellular protein level as a function each fragment type over time. Each data point
represents the mean of three values, and error bars denote SEM.
Asterisks denote statistical differences (p<0.05) in lactic acid levels with respect to time.

Alkaline Phosphatase
The ALP activity level of PDBM increased over the course of the study (Figure
22). A significant increase (p < 0.05) occurred in ALP activity of cells seeded on PDBM
fragments between Day 13 and Day 36. No significant ALP activity level differences (p
> 0.05) were noted for the cellular CDBM and NDBM cultures (Figure 22).
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Figure 22 Alkaline phosphatase activity
ALP levels as a function of each fragment type over time. Each data point represents the
mean of three values, and error bars denote SEM.
Asterisks denote statistical differences (p<0.05) in lactic acid levels with respect to time.

Extracellular Calcium
A significant decrease (p < 0.05) was found when comparing the level of
extracellular calcium from PDBM samples from Day 13 and those from Day 24; a
significant increase (p < 0.05) was noted when comparing samples from Day 24 and Day
36 (Figure 23). Larger levels of extracellular calcium were measured in PDBM than in
cultures CDBM and NDBM cultures.
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Figure 23 Extracellular calcium
Extracellular calcium levels as a function of each fragment type over time. Each data
point represents the mean of three values, and error bars denote SEM.
Asterisks denote statistical differences (p<0.05) in lactic acid levels with respect to time.

Gene Expression

Real-Time RT-PCR
RNA concentrations, rRNA ratios, and integrity values obtained from the
bioanalzyer are displayed in Table 9. Data displayed in Table 10 shows the number of
reactions that occurred with respect to time for each gene studied. A maximum of three
reactions were possible since three replicates were run for each fragment/time point
combination. All Day 4 PDBM fragments demonstrated reactions at approximately the
same cycle number. This is also true for Day 36 PDBM samples. Runx2 was not
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expressed in Day 24 samples but BSP and OCN was expressed in all replicates for Day
24 PDBM samples. The number of CDBM replicates expressing Runx2, BSP, and OCN
increased with time from Day 4 to Day 24.

CDBM Day 36 cellular cultures

demonstrated a decline in the number of replicates expressing BSP and OCN reactions,
while three continued to express Runx2. Two Day 4 NDBM culture replicates expressed
Runx2 and OCN, while replicate cultures from the remaining conditions and time points
all had reactions indicative of Runx2 and OCN presence.
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Table 9 Bioanalyzer results
Bioanalyzer results showing the RNA concentration and integrity of RNA samples
Note: N/A (not applicable) values result from undetectable values
Fragment
Type
PDBM
PDBM
PDBM
CDBM
CDBM
CDBM
NDBM
NDBM
NDBM
PDBM
PDBM
PDBM
CDBM
CDBM
CDBM
NDBM
NDBM
NDBM
PDBM
PDBM
PDBM
CDBM
CDBM
CDBM
NDBM
NDBM
NDBM
PDBM
PDBM
PDBM
CDBM
CDBM
CDBM
NDBM
NDBM
NDBM

Time point
4
4
4
4
4
4
4
4
4
13
13
13
13
13
13
13
13
13
24
24
24
24
24
24
24
24
24
36
36
36
36
36
36
36
36
36

RNA concentration
(ng/µL)
45
22
34
43
29
27
23
34
59
81
47
50
88
84
26
57
60
58
42
48
18
37
27
26
23
35
23
41
31
15
22
27
14
26
23
21
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rRNA ratio
(28s/18s)
2.0
2.2
2.4
2.0
2.0
2.1
0.0
2.6
2.6
2.3
2.4
2.5
2.2
2.2
0.0
2.5
2.4
2.4
2.4
2.4
2.3
2.3
2.2
2.4
0.0
2.3
0.0
2.0
2.0
1.9
2.2
1.9
0.0
2.4
2.3
1.6

RNA
Integrity
10.0
10.0
N/A
10.0
10.0
N/A
2.5
10.0
N/A
10.0
10.0
9.9
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
9.6
N/A
9.8
10.0
2.6
10.0
2.6
10.0
10.0
9.5
9.5
9.8
9.7
N/A
9.7
N/A

Table 10 Real-time RT-PCR
Number of real-time RT-PCR reactions that occurred for each gene for each fragment
type. The maximum number of reactions is three, since three replicates were run for each
fragment condition at each time point.
Fragment Type
PDBM
PDBM
PDBM
CDBM
CDBM
CDBM
NDBM
NDBM
NDBM

Day RUNX
4
3
24
0
36
3
4
1
24
3
36
3
4
2
24
3
36
3
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BSP
3
3
3
2
3
2
3
3
3

OCN
3
3
3
2
3
2
2
3
3

DISCUSSION
Evaluation of Media Cocktails
The first stage of this research was to determine if osteogenic media supplements,
specifically β-glycerophosphate and L-ascorbic acid, affect the cellular activity of D1
cells seeded on partially demineralized bone matrix when they are added to the media
cocktail. The results of this study guided the media designation for the studies involving
D1 cells and DBM.
Stereomicroscope images of DBM fragments prepared for the media study
demonstrate that the particles have varying size, shape, and thickness, even though all the
fragments were prepared in the same manner (Figure 4). The stereoscope images also
show that the bone fragments demineralized at varying rates.

After 80 minutes of

demineralization, many fragments were partially demineralized; some were slightly
demineralized; while others were either completely or almost completely demineralized.
Images obtained after von Kossa staining on Day 4 (Figure 7) also demonstrate the
variability in the mineralization levels of the bone fragments.

It is likely that the

variability in the demineralization rates occurred because of the initial variability in the
size, shape, and thickness of the bone fragments.
Microscopic analysis of the substrates during the media cocktail study show that
the cells adhered to the bottom of the well plate, while images obtained from cytotoxicity
assays show that the cells also adhered to the surfaces of the bone. The wells of the 24well plates were coated with Sigmacote™ prior to cell seeding. Sigmacote™ was designed
to create a hydrophobic film with a neutral pH, that prevents proteins from adhering to
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glass surfaces [56]. Although Sigmacote™ has been shown to efficiently coat select
plastic surfaces, this product is not guaranteed to efficiently coat all film on plastic
surfaces [56]. The cellular attachment on the well bottoms suggests that the coating
process was not completely effective. As a result, the number of cells that initially
attached to the bone surface likely differed between wells and also within each well. This
situation could cause skewed results if, for example, a large difference was noted in the
attachment levels on the substrates.
A significant difference in the total lactic acid production on Day 24 between the
two media conditions indicates that PDBM substrates cultured in media containing
osteogenic supplements were in a more acidic environment than those contained in the
media without osteogenic supplements. Medium acidity can affect the cellular activity of
cells in the medium. Below an extracellular pH of 7.1, osteoblast differentiation can be
hindered [13]. The medium was slightly orange on later days of the study, indicating that
the medium was not at an ideal pH. The medium should remain at a pH of 7.0-7.4 due to
sodium bicarbonate in the initial medium solution. A color change indicates that the
medium was either below a pH of 7.0 or nearing the outer bounds of the pH range
indicated for α-MEM [13].
Histological and cell viability images indicate that D1 cells attached to the PDBM
and CDBM substrates by Day 4. While some areas of the bone fragments appeared to
increase in cellular number throughout the first study on both fragment types, other areas
appeared to decrease. This decrease in cell number could be correlated to an increase in
cell numbers that were rapidly proliferating on the surface of the wells. Between Days 13
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and 24, the cells that were attached to the OSTEO AND NOSTEO system (PDBM
fragments cultured with and without osteogenic supplements) well bottoms began to
detach from the surface. The lower pH may have caused the detachment of cells from the
substrates and wells, resulting in the lower number of cells visible on the surface OSTEO
and NOSSTEO substrates on Day 24.
Relative comparisons of metabolic activity on 3D substrates can vary with cell
cycle and cell number. For instance, a population of cells in the synthesis phase of cell
growth spend their energy duplicating into daughter cells via DNA replication.
Conversely, cells in the G0 (resting) stage of interphase are not dividing and may be
characterized by a different metabolic activity level than cells in the synthesis phase.
Cells that are reacting negatively to a substrate may exhibit a spike in metabolic activity.
Thus, the drop in metabolic activity level between Days 4 and 13 on the OSTEO (PDBM
cultured with osteogenic supplemented media) and NOSTEO (PDBM cultured without
osteogenic supplements) cultures could indicate that more cells were in the resting phase
on Day 13 than on Day 4. The increase in metabolic activity level from Day 13 to Day
24 for OSTEO and NOSTEO cultures could mean that fewer cells were in the resting
stage on Day 24 than at the previous time point. The metabolic activity assay, however,
only yields a very general idea of the activity of the cells over 24 days. A more accurate
picture might be obtained if the metabolic activity level was observed more often,
perhaps at each medium change.
Figure 12 shows that, as time increased, the level of ALP also increased for all
conditions. ALP, an active enzyme expressed in the plasma membrane of osteoblasts, is
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an indirect indicator of the osteoinductivity of the DBM [13, 14]. It has been suggested
that a direct correlation exists between the amount of ALP activity and the amount of
new bone generation as induced by the scaffold [57].

ALP is required by the

extracellular matrix for mineralization to occur within the scaffold [13, 57]. The increase
in extracellular calcium in the samples cultured in medium containing osteogenic
supplements suggests that mineralization of the samples is occurring.
Higher levels of protein were detected on the cellular control samples than on any
of the other samples on Day 4 and Day 13. The control samples also had higher ALP
levels on Day 13 and Day 24 than either experimental PDBM sample set. GnHCl
treatment has been shown previously to be effective in removing osteoinductive proteins
from substrates [58]. GnHCl extracts the BMPs from the substrate, resulting in inability
of the substrate to induce bone formation [5]. The control substrates are osteoconductive,
as evidenced by the cell attachment viewed through histological and live/dead images.
These results suggest that the medium has a greater influence than the substrate on the
proliferation and differentiation of the D1 cells.
No significant differences (p > 0.05) were detected between the two medium
conditions on any particular time point with regard to the intracellular protein content,
ALP activity, and extracellular calcium levels. The results of the assays performed on
lactic acid and glucose levels, metabolic activity, and intracellular protein levels suggest
that D1 cells proliferated on OSTEO (PDBM fragments cultured with ostegenic
supplements) and NOSTEO (PDBM fragments cultured without ostegenic supplements)
substrates [13]. Although significant differences existed between the metabolic activities
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of the two experimental groups, no significant differences due to medium specification
were evident with regard to proliferation and differentiation of D1 cells seeded on PDBM
scaffolds.
Past research has shown that bone marrow stromal cells extracted from mice, and
cultured in medium containing β–glycerophosphate and ascorbic acid, formed cells with
polygonal morphology [59]. The polygonal cells from Falla’s study stained positively
following von Kossa staining, indicating that mineralization occurred [59]. In the same
study, when one of these two media supplements was not added to the medium cocktail,
mineralization did not occur [59]. Dexamethasone (Dex), a glucocorticoid, is often
added to media as an osteogenic supplement since research has shown that the addition of
this glucocorticoid leads to an increase in osteoblast marker expression in cell cultures
with primary rat calvaria and primary rat marrow cells [13, 60, 61]. Although still used
in medium cocktails when bone formation is a desired outcome, dexamethasone has been
shown to inhibit bone formation in primary mouse marrow stromal cells [59].

In Vitro Evaluation of DBM

The second stage of this research was to evaluate the effects of the
demineralization level on cellular activity over time. The cellular activity of cells seeded
on completely demineralized bone fragments was compared to the cellular activity of
cells seeded on partially demineralized bone fragments.
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An alternative method of bone preparation was employed for the final evaluation
of DBM.

Stereomicroscope images taken before and during demineralization

demonstrated that the bone fragments were more similar in physical structure when a
rotor speed mill was used to grind the larger bone fragments into small pieces than when
they were prepared for the media cocktail study. Images of fragments after 80 minutes of
demineralization showed that the majority of the fragments had demineralization levels
similar to each other (Figure 14). Although there were a few outliers which either
demineralized quicker or slower than other fragments, the majority of the bone fragments
had mineralized cores consistent with one another. Demineralization appeared to have
occurred at a more consistent rate (Figure 14) than in previous demineralization attempts.
Von Kossa images of the bone fragments at Day 4 (Figure 17) also support the theory
that the PDBM fragments used in this study had consistent demineralization levels.
CDBM fragments also showed complete demineralization in images obtained from
stereomicroscopy and after von Kossa staining. Some of the CDBM fragments had small
flecks of mineralized areas. Although stereomicroscope images made it appear that the
fragments were completely demineralized, the fragments may have been able to undergo
another

demineralization

cycle;

however,

care

was

taken

to

avoid

excess

demineralization of the bone fragments. Previous research has revealed that excessive
demineralization decreases the osteoinductive properties of the substrate [5].
Due to the inconsistency with the Sigmacote™ well treatments, ultra-low
attachment well plates were used for the final study.

Microscopy of the cells and

substrates throughout the study revealed that the cells did not adhere to the bottom of the
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wells. LIVE/DEAD image analysis confirmed the lack of cells on the surface of the
wells and the presence of cells covering the surface of the substrates (Figure 15). A
direct comparison of the difference in the attachment of D1 cells on the bone fragments
can be made from PDBM samples cultured in osteogenic supplemented media from the
media cocktail study and PDBM samples in the final study. PDBM samples from the
second study were more evenly demineralized than OSTEO fragments from the first
study. On average, the PDBM samples had smaller demineralized cores than OSTEO
fragments. On Day 4, a larger number of cells were detected on the PDBM samples than
on the OSTEO samples. These fragments were cultured in the same media and both
contained partially demineralized bone fragments. The ultra-low attachment plates and
the consistency in fragment processing and demineralization likely improved the
environment for cell attachment.

It is also possible that the surfaces of the bone

fragments differed between the two bone preparation methods. Cells might have been
able to attach to the PDBM samples more readily than OSTEO samples.
All sets of bone fragments were metabolically active throughout the course of the
study, as noted by the increase in lactic acid production and glucose uptake (Figure 1819). Again, significant differences in metabolic activity via Alamar Blue™ (Figure 20)
might demonstrate changes in cell cycle. The data from the lactic acid analysis, the
glucose analysis, and the metabolic activity analysis show that the D1 cells were
metabolically active on the PDBM, CDBM, and NDBM substrates.
As time progressed, the thickness of the cell layers attached to the outside of the
bone fragments increased between each subsequent time point, as indicated by the H&E
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images (Figure 16). By the end of the study, the PDBM fragments had more cell layers
on the surface of the bone fragments than CDBM fragments and it appears that there was
greater cellular infiltration of the PDBM fragments as compared to infiltration of the
CDBM fragments.
It appears, based on the von Kossa images, that the cells on the PDBM fragments
were causing mineralization (Figure 17). Images of the early time point specimens show
the lining of the mineralized bone core with smooth edges; on the 24th day this edge,
separating the mineralized and demineralized areas, was uneven and there were small
specks of mineralized bone just outside the mineralized core. Day 36 von Kossa images
show a very uneven line between the mineralized and demineralized areas of the bone. It
is difficult to decipher if the cells on the CDBM fragments caused mineralization by the
end of the study; since some of the fragments were not completely demineralized. It is
not known whether or not the mineralized areas on Day 36 are a result of the fragments
not being completely demineralized or a result of cellular mineralization.
Similar trends, showing a significant increase (p < 0.05) in intracellular protein
between Days 4 and 13 and a drop in level between Days 13 and 24, followed by another
significant (p < 0.05) increase between Days 24 and 36, occurred on both the PDBM and
CDBM samples. These trends indicate that proliferation of D1 cells on the substrates
occurred at approximately the same time points. An improved view of the differences in
cellular response to the two fragments might be determined if the assay is run more
frequently. Overall, there was an increase in proliferation over the course of the study.
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ALP levels appeared to be consistent for the CDBM samples. A significant
increase in cellular ALP levels was observed between Days 13 and 36 on the PDBM
fragments. A combination of an increase in ALP activity and higher cell numbers within
the PDBM fragments suggests that the oxygen and nutrients were adequate for cell
growth and differentiation [62]. An increase in ALP activity was not noted for the
CDBM fragments but an increase in cellular infiltration (H&E images) was noted over
time.

This behavior might indicate that differentiation was inhibited by the media

conditions, such as the low pH.
The increase in cellular attachment and infiltration of the cells indicates that
cellular proliferation did occur. It is possible that the PDBM fragments released BMPs at
a more ideal rate than did the CDBM fragments, allowing osteoblast formation [38].
Chondrocytes and osteoblasts express ALP [63]. The presence of ALP activity suggests
that the culture system can induce bone formation, although this point is not guaranteed.
An in vitro study by Zhang showed that over a range of residual calcium content
percentages, 32.7%-1.2%, ALP activity level increased as the residual calcium level
decreased from 32.7% to 2%. A subsequent decrease in ALP activity level was observed
as the residual calcium level continued to decrease from 2% to 1.2% [5]. The lower ALP
activity levels by cells seeded on CDBM substrates, as compared to PDBM substrates,
indicates that the in vitro data obtained from this study correlate with Zhang’s data. If the
lower ALP values were not observed for the CDBM cultures it would not mean that the
study contradicted previous work since the residual calcium levels before culture were
not measured; therefore, the placement of the ALP activity levels on a bell curve (as

92

demonstrated by Zhang’s data) is unknown. A review of clinical cases involving surface
decalcified bone states that it is easier to contour the surface decalcified implants for the
defect site [64]. It is not known what the surface decalcified implant is compared.
An in vitro study, reported in 2005 [33], evaluated the ALP activity of partially
demineralized and fully demineralized substrates on Days 7 and 14 and resulted in
similar ALP activity patterns as observed in the current study. ALP activity levels did
not change drastically over time for the fully demineralized substrates, but increased for
the partially demineralized substrates. It has been suggested that the difference in activity
between PDBM and CDBM substrates could be that, as demineralization continues,
osteogenic factors are removed, or that hydroxyapatite nucleation sites are exhausted
[33]. The osteogenic factors that are exposed during demineralization are thought to
recruit MSCs, which facilitate the bone induction principle [33, 36].
The consistent level of extracellular calcium in the NDBM and CDBM samples
demonstrates that the cells in these samples were not mineralizing.

The low and

consistent levels of calcium could be a result of some of the fragments not being
completely demineralized before seeding with cells and resulting in the release of
calcium during the assay process. The PDBM samples had varying levels of calcium
over the four time points studied. It is possible that human error caused the variation in
results for the decrease in extracellular calcium. Perhaps when the lysates were removed
from the wells for this assay they were not mixed properly causing the contents to be
evenly distributed which would cause a skew in the results. This study did not include
determining the extracellular calcium levels of fully mineralized bone fragments. If the

93

extracellular calcium level of fully mineralized bone fragments was known, then a
comparison could be made concerning the amount of mineralization occurring over time
for each of the sample groups.
RNA samples were inadvertently thawed for an unknown amount of time while
they were in the -80°C freezer. RNA samples from Days 4, 13, and 24 were rerun on the
Bioanalzyer once this problem was observed and it was determined from comparison of
the results that Day 13 samples were not suitable for analysis since they were almost
completely denatured (Table 22).

When real-time RT-PCR was run, the data was

acquired during the annealing stage.

Therefore, it is inaccurate to run quantitative

analysis on this data. It is feasible to determine if reactions occurred for each RNA
sample. Table 23 shows that reactions occurred for all samples on all time points for all
genes studied except for Runx2 on Day 24 for the PDBM samples. Mature genes such as
osteocalcin were present in the CDBM and PDBM cultures. Other assays, such as von
Kossa staining, completed on CDBM fragments did not show signs of mineralization. If
signs of mineralization were evident, mature genes would be expected. The relative
levels of gene expression are unknown so it is possible that the genes are expressed in
low levels from CDBM samples and higher levels in PDBM samples, since
mineralization appeared to occur in PDBM samples. Also, the presence of genes from
real-time RT-PCR does not automatically mean that protein translation occurred in vitro,
just that it has the possibility to occur. Real-time RT-PCR is measuring the protein
translation from the reaction of the RNA with the primers and not the protein translation
that occurred in vitro. Real-time RT-PCR should be repeated and data gathered during
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the extension phases to give a better idea of the osteoblast activity over the course of the
study since the RNA is being amplified during these stages.
The results presented in this thesis demonstrate that a difference in cellular
activity was noted between PDBM and CDBM samples. These differences appear to be
at which time points the cells were proliferating and differentiating. Thorough research
on more time intervals should be completed to see these differences more accurately.
This research appears to corroborate findings from other studies involving the differences
between bone fragments of varying demineralization methods.

Although it is also

difficult to compare extracellular calcium levels, ALP activity levels, intracellular protein
levels, and metabolic activity levels between this study and studies performed by other
researchers due to discrepancies between preparation of samples and the specific
equipment used, it is possible to note when and if cells are proliferating and
differentiating.
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CONCLUSIONS
Qualitative microscopy and quantitative assays indicate that D1 mouse stromal
cells attach to PDBM substrates and subsequently proliferate and differentiate, regardless
of whether the samples are cultured in medium containing osteogenic supplements.
Contrary to prior results in the literature, the substrates cultured in medium containing
osteogenic supplements did not differentiate faster than cells in the medium, without
osteogenic supplements.

Although the intent of the medium study was to examine

partially demineralized substrates, visual analysis showed that the level of the substrate
demineralization was minimal and variable.

This variability likely caused skewed

results.
Qualitative and quantitative assays also indicated that D1 cells attach to,
proliferate, and differentiate on PDBM and CDBM scaffolds. The metabolic activity of
the cells on the two scaffolds appeared to be similar. The proliferation and differentiation
levels of D1 cells on the PDBM and CDBM scaffolds were significantly different on Day
24 of the study. According to von Kossa images and the varying levels of extracellular
calcium extracted from the PDBM scaffolds, mineralization of the PDBM occurred
between Day 24 and Day 36. Although the cells proliferated and differentiated on
CDBM fragments, the assays performed showed no evidence of mineralization. The
reactions that occurred from real-time RT-PCR demonstrate that cells were
differentiating towards the osteoblast phenotype.
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RECOMMENDATIONS

Further evaluation of the DBM scaffolds and preparation of the scaffolds is
needed to fully evaluate the effectiveness of the scaffolds and the differences in bone
formation triggered by PDBM versus CDBM samples. Additional studies should be
performed to determine if the addition of dexamethasone to the media cocktail has
inhibitory effects on bone formation.
Media conditions were acidic before each media change; decreasing the
DBM/media proportion might allow a more physiological pH and higher rate of cellular
proliferation and/or differentiation.
Further evaluation of the cellular activity of the cells needs to be completed in
order to gain a better overall understanding of the cellular activity of the cells over time.
All assays should be completed on Day 0 samples to offer a better comparison between
later time points and the initial seeding of cells on the scaffold. Metabolic activity,
intracellular protein, ALP, and extracellular calcium assays should be performed more
often to gain a better overall understanding of the activity of the cells seeded on the
substrates. Real time RT-PCR should be repeated in order to elucidate which genes are
being expressed over time and to obtain a better understanding of osteoblast maturation
in this system.
Previous studies examining the DBM substrates showed that the control culture,
NDBM, had cellular activity similar to that found in PDBM and CDBM cultures. The
activity of cells cultured on 2D surfaces in varying media conditions should be
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investigated to determine if the proliferation and differentiation of D1 cells into
osteoblasts can result from the media alone.
Studies should be performed to determine if the size of the bone particles might
affect the ability of the cells to proliferate and differentiate. If a specific size fragment
allows for greater cell to bone surface area then it is possible that this specific fragment
size might be optimal for differentiation of the cells into osteoblasts.
In order to more completely evaluate the effectiveness of the proposed DBM
preparation methods and the assays in an in vitro setting, in vivo studies should be
conducted to assess the effects of DBM in a critical sized defect.

This step will

necessitate refining the DBM processing variables so that all fragments are of equal size,
shape, thickness, and mineralization level.

The in vitro characterization should be

compared to the in vivo characterization to determine the efficacy of the in vitro model.
In vivo models that demonstrate the effectiveness of DBM when care is taken in the
processing of the scaffold might help companies and bone banks understand the
importance of standardizing the preparation methods of DBM products.

Once an

accurate in vitro model is established, it would interesting to evaluate the effects of nonsteroidal anti-inflammatory drugs (NSAIDS) on the ability of the DBM scaffold to induce
bone formation, since patients might receive these drugs as they are recovering from
surgery or during the course of their recovery.
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APPENDICES
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Appendix A
H&E Staining Protocol
1. Rehydrate sections
a. 100% ETOH
b. 100% ETOH
c. 95% ETOH
d. 95% ETOH

10 dips
1 min
10 dips
1 min

2. Rinse in running tap water until “sheeting” action occurs
3. Soak in distilled water for one minute
4. Stain with hematoxylin for 5 minutes.
5. Rinse in running tap water until clear
6. Perform 12 dips in clarifier
7. Rinse in running tap water until “sheeting” action occurs
8. Soak in bluing reagent for one minute
9. Rinse in running tap water for one minute
10. Perform 10 dips in 95% ETOH
11. Stain with eosin for 45 seconds
12. Rinse in 2 changes of 95% ethanol. Perform 10 dips in each.
13. Rinse in 2 changes of 100% ethanol. Perform 10 dips in each.
14. Soak in 100% ethanol for one minute
15. Perform 10 dips in xylene followed by a 5 minute soak
16. Mount with paramount.

* This protocol was slightly modified from RICHARD-ALLAN™ HEMATOXYLIN &
EOSIN protocol
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Appendix B
Von Kossa Staining Protocol for GMA
1.

Rehydrate sections.
a. Soak in 100% Ethanol for 2 minutes.
b. Soak in 95% Ethanol for 2 minutes.
c. Soak in distilled Water for 2 minutes.

2. Stain with 2% silver nitrate for 30 minutes in sunlight or UV light.
3. Rinse slides thoroughly with distilled water until water is clear.
4. Stain with hematoxylin for 6 minutes.
5. Rinse slides thoroughly with distilled water until water is clear.
6. Rinse with 0.25% ammonium hydroxide for 10 seconds.
7. Rinse slides thoroughly with distilled water until water is clear.
8. Stain with 0.3% eosin Y for 5 minutes.
9. Rinse slides thoroughly with distilled water until water is clear.
10. Rinse with 2 changes of 95% Ethanol. Perform 15 dips in each.
11. Rinse with 2 changes of 100% Ethanol. Perform 15 dips in each.
12. Soak in xylene. Perform 10 dips followed by a 1 minutes soak.
13. Soak in xylene for 5 minutes.
14. Mount with paramount.
* Protocol was obtained from Dr. Chuck Thomas (dissertation) and slightly modified.
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Appendix C
Primer Design Protocol
1. On the National Center for Biotechnololgy Information’s (NCBI) webpage,
www.ncbi.nlm.nih.gov/, search for the gene(s) of interest.
2. Locate appropriate gene and follow the link to the mRNA sequence on the
GenBank data page.
3. Highlight and paste the sequence into the nucleotide/nucleotide BLAST search at
www.ncbi.nlm.nih.gov/BLAST. Choose a homologous mRNA sequence that
contains a “complete CDS” sequence
4. Paste the mRNA CDS sequence into the mRNA sequence box in Spidey found at
www.ncbi.nlm.nih.gov/IEB/Research/Ostell/Spidey/
5. Paste the original genomic sequence from step 1 into the genomic sequence box
on the Spidey webpage.
6. Align the genomic and mRNA sequences in Spidey.
7. Open the Primer 3 homepage, frodo.wi.mit.edu/cgibin/primer3/primer3_www.cgi. Paste in the mRNA derived complete cds from
the NCBI page
a. The search parameters should be set as follows:
i. Human mis-priming library
ii. Create a new sequence ID for the primer
iii. Product size range: 100-150
iv. Number of results to return: 10
v. Primer Size: 18/20/22
vi. Melting Temperature: 60/62/65
vii. GC%: 40/50/60
viii. Mex self-complimentary: 5
ix. Max 3’ complimentarity: 2
x. Max Poly-X: 3
xi. GC clamp: 1
b. Search for primers
8. From the Primer 3 output, choose a primer that is close to the 3’ end, binds to
portions of at least 2 different exons (ideally with >400 basepairs intervening the
genomic sequence).
9. Validate primer choice by copy and pasting the forward primer into BLAST,
typing in at least 10 intervening bases. Coping and paste in the reverse primer
immediately following the intervening base pairs. Perform BLAST search.
10. Verify that the expected products match the targeted gene.
11. Order primers from Integrated DNA Technologies (IDT) using the primer
sequences from Primer 3 for each targeted gene.
* This protocol was obtained from class notes presented by Dr. Ken Webb for a
Bioengineering Cell Analysis Class
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